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 The main challenge in disease treatment is no more the discovery of new therapeutic 
drugs, but to provide targeted delivery of therapeutic drugs to specific sites without incurring 
systemic toxicity effects.  An efficient way of reducing the toxicity is by encapsulating the drug 
with a biodegradable matrix that can provide controlled release of the drug along with local 
heating of the drug. Local heating can be obtained by incorporating magnetic iron oxide particles 
that heat upon exposure to AC electromagnetic fields.  The magnetic iron oxide nanoparticles are 
also gaining much attention as MRI contrast agents.  Thus it would be of potential benefit if a 
drug delivery system is designed to encapsulate the drug as well as the magnetic iron oxide 
nanoparticles within a biodegradable matrix, thereby providing a dual modal imaging and 
therapeutic delivery system.  The key step in the design of a dual modal drug delivery system is 
xvi 
 
the encapsulation of the magnetic iron oxide nanoparticles with polymer of choice. The magnetic 
iron oxide nanoparticles were encapsulated into a robust poly (styrene-co-vinylbenzylchloride-
co-divinylbenzene) (PSVBDVB) to study these synthetic variations upon encapsulation with a 
polymer.  The next step to the design of drug delivery system was to replace the PSVBDVB 
polymer by a biocompatible and biodegradable polymer- Poly (lactide-co-glycolide) (PLGA). 
The PLGA composites containing the Fe@FeOx core shell nanoparticles and the drug analog 
[Ru(bpy) dye] was prepared by oil-in water emulsion solvent evaporation technique.  The local 
heating of the PLGA composites was also achieved by irradiating the Fe@FeOx nanoparticles 
with 2.45 GHz microwave radiations.  Higher Ru(bpy) dye release from the composites by 
locally heating the sample with 2.45 GHz microwave pulse compared to externally heating the 
composite sample was achieved. 
 The final step was the design of controlled release drug delivery system with dual modal 
imaging and therapeutic capabilities.  To obtain narrow sized PLGA composites the Fe@FeOx 
nanoparticles were replaced by chloroform based ferrofluid.  The ferrofluid was synthesized by 
novel thermolysis technique.  The release of the dye from the PLGA composites when placed in 
the Rf induction coil was determined by fluorescence spectroscopy and a linear increase in the 
fluorescent intensity was observed with time.  Also, the controlled release of the dye from the 
composites was achieved by a pulsed Rf treatment.  Magnetic resonance imaging was also 
performed using the PLGA composites which showed enhancement in the T2-weighted image 
contrast and thus negligible reduction in the contrast capabilities of the iron oxide particles (R2 = 
58.7 s
-1
mM
-1
).  The PLGA composites containing the drug analog and the iron oxide 
nanoparticles thus constitute a controlled release drug delivery system with dual modal imaging 
and therapeutic capabilities. 
        
   
 
 
 
 
 
 
 
 
 
 
 
Chapter 1. Introduction 
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1.1.Overview 
 Advances in the drug development and delivery have evolved in several phases, 
beginning with the botanical phase of human civilization, via the synthetic chemistry era, and 
now presently in the biotechnology era.  Researchers are continuously developing new and 
more powerful drugs, but still the drugs are administered conventionally.  The conventional 
route of administration of these drugs are primarily enteral or perenteral routes.  Enteral route 
of drug administration rely on introducing a drug to the digestive tract through the mouth or 
rectum.  Perenteral route of drug administration involves the injection or infusion of a drug into 
the body  (intravenous or intramuscular).
1,2
 Many vaccines as well as the chemotherapeutic 
drugs are delivered through the perenteral route of administration.
1
  Oral delivery is most 
attractive due to high patient convenience and compliance.  In both type of administration the 
resultant effect is systemic i.e. upon administration the drug molecules are distributed 
throughout the body. 
3,4
  Several different types of cell are involved into the diseased tissues: 
the diseased cells, normal cells from which the disease evolves, vascular cells, fibroblasts, and 
immune cells.  The systemically distributed drug metabolizes throughout the body leading to 
the damage of healthy cells and tissues, resulting in general toxicity and poor acceptance of the 
treatments by patients.
4
  For example, the treatment of cancer, HIV infections, tuberculosis, 
and malaria generally involve very powerful drugs, and their use is considerably reduced due 
to the occurrences of side effects. In addition, conventionally delivered drugs get diluted in the 
blood and body fluids resulting in insufficient drug concentration at the diseased site.
5
  Drugs 
are often too quickly cleared from the blood stream due to the uptake by the reticuloendothelial 
system (RES) i.e. the body’s immune system, and the kidneys.5  This leads to a treatment 
approach of higher doses, or the inconvenience of continuous infusion again resulting in 
3 
 
perhaps intolerable or even more toxic levels of drugs.
4
  This side effects result in a dose 
limiting situation where the drug administration has to be brought to a level that is just 
tolerable to the patients, but may be less effective.  Also the drugs may be unstable and 
degrades quickly or may have a very poor solubility in aqueous solution. For instance 
hydrophobic drugs get precipitated in blood plasma, and require solubilizers/stabilizers in order 
to administer the drugs.
6
  Unfortunately, these solubilizers/stabilizers not only dilutes the 
potency of the drugs but also adds up to the drug toxicity.
7
  Therefore, for effective treatment 
it is necessary to maintain the drug concentration between the effective therapeutic level 
and the maximum tolerable limit for prolonged period of time as shown in figure.
8,9
  The 
drug release from conventional route is in a form of a burst where in the drug is released all at 
a time and needs to be given on a regular basis.  A controlled release drug delivery system is 
desirable that can release the drug effectively in the therapeutic window over a long period of 
time. This will allow for fewer drug dosage and patient compliance.  This all can be achieved 
by designing a controlled release drug delivery system specific for the diseased cells within the 
body.  The challenges presented here can be overcome by properly integrating nanotechnology 
with the established knowledge of the disease characteristics. 
4 
 
 
Figure 1-1: Therapeutic window showing the effect of conventional burst release and 
controlled release relative to the effective concentration and the maximum tolerable toxic 
concentration. 
 
1.2. Nanotechnology 
Nanotechnology is an emerging field of science that can facilitate a way to overcome the 
short coming to an efficient and safe drug delivery system.
10,11
  Nanotechnology is an 
interdisciplinary field of science which deals with the design, synthesis, characterization and 
application of devices and materials in the nanoscale range.
4
  Although nanomaterials are 
widely considered to be an invention of modern science, they actually have a very long history. 
5 
 
Nanoparticles (NPs) were empirically used by artisans as far back as the 9th century BC in 
Mesopotamia to generate a glittering effect on the surfaces of pots.  Modern nanotechnology 
was envisioned by the physicist and Nobel laureate Richard Feynman in his lecture “There is 
plenty of room at the bottom” in 1959.  Nanotechnology refers to structures roughly in the 1 to 
500 nm size in at least one dimension and are developed by top-down or bottom-up 
approaches.
12
   To put this size range in perspective, an atom, molecules, proteins, virus, cell 
mitochondrium, red blood cells, and the mammalian cells are around 0.1 nm, 1 nm, 10 nm, 100 
nm, 1000 nm, 10,000 nm and 100,000 nm respectively as shown in Figure 1-2.  The application 
of nanotechnology to life sciences has been termed as nanobiotechnology.
13-15
 
 
Figure 1-2:  Representation of size of species in the nano and micron region 
These nanoscale materials possess unique and unusual properties and are currently used 
in multidisciplinary scientific areas that range from physics and engineering to biochemistry.   
Among many unique physical and chemical properties at the nanoscale, one basic physical 
property for nanomaterials is the large surface area to volume ratio.
16
  For example, in bulk 
materials only a relatively small percentage of atoms can be at or near the surface. When the 
6 
 
dimensions continue to shrink to the nanoscale, the percentage of bulk atoms decreases while the 
surface atoms increase.  This provides relatively large (functional) surface area which is able to 
bind, absorb and carry other compounds such as drugs and probes.
17
  Also the physiochemical 
properties of nanomaterials like friction and interaction with other molecules are different from 
their bulk counterparts.  Depending on the type of application nanomaterials can be synthesized 
from different materials like iron, gold, silica, semiconductors, lipids or polymers.  Also the 
nanomaterials can be fabricated into different shapes such as nanospheres, nanorods, nanotubes, 
nanowires.  The nanomaterials due to their small size can cross biological barriers including the 
blood-brain barrier, transit out of blood vessel walls or the cells by difference uptake 
mechanisms thereby interacting with wide range of biological entities.  These characteristics 
confer nanomaterials high interaction and transport capabilities making them attractive for the 
design of biosensors, imaging and/or therapeutic agents.  Advances in nanobiotechnology have 
heralded the advent of several innovative nanomaterials, which are set to revolutionize the field 
of targeted drug delivery system. 
1.3. Drug delivery system (DDS) 
A drug delivery system (DDS) is defined as a system in which the bioactive agent (drug) 
is integrated with a non-active agent (carrier) in such a way that the drug is released from the 
carrier in a predetermined manner, at a constant rate in what is known as zero-order release, in a 
cyclic manner, or in response to an external trigger such as a change in pH, ionic strength or 
temperature of the medium.
18-21
   Ideally the carrier system, whether it is synthetic or natural, 
should be able to provide a nontoxic support system that can be manufactured on an industrial 
scale that can be translated into a cost-effective, clinically practical medicine.
22
  In addition to 
controlling the rate and duration of the drug release, the DDS should be able to target the drugs 
7 
 
to specific organs and tissues, as well as individual organelles within the individual cells (i.e. 
tumors, bacterial cells of definite species) or respond to a biofeedback mechanism such as 
glucose levels in hyperglycemia patients.  The schematic of an ideal drug delivery system is 
depicted in Figure 1-3. 
   
Figure 1-3: Schematic representation of an ideal drug delivery system (DDS) 
 The benefits offered by controlled DDS over traditional pharmaceutical administration 
include maintenance of the drug levels within desired limits, maximize the pharmaceutical drug 
8 
 
activity, the need for fewer doses, and better patient compliance.
23
  In addition, association of the 
drug with a carrier may provide enhanced protection to the active agent from degradation in the 
physiological environment, and improve the stability of the drug that is required for formulation 
and administration.  The field of DDS is characterized by the need of delivering the existing 
drugs to specific targets in the diseased cells through specific cell reorganization 
mechanism and be able to overcome the biological barriers that prevent the drug from 
effectively reaching the target.  
19,24-27
  The application of nanobiotechnology to drug delivery 
has benefited all streams of medical science with oncology being the foremost 
1.4. Cancer  
 Cancer is a class of disease in which the cells in a part of the body begin to grow out of 
control.
28
  Cell multiplication (proliferation) is a normal physiologic process that occurs in 
almost all tissues and under many circumstances, such as response to injury, immune responses, 
or to replace cells those have died or have been shed as a part of their lifecycle.  Normally the 
balance between proliferation and cell death is tightly regulated to ensure the integrity of organs 
and tissues.  But sometimes mutations in the DNA disturb the orderly process and leads to the 
uncontrolled and often rapid proliferation of cells.  This leads to either a benign tumor or a 
malignant tumor (cancer).  Benign tumors do not spread to other parts of the body or invade 
other tissues, and they are rarely a threat to life. Malignant tumors can invade other organs, 
spread to distant locations (metastasize) and become life threatening.  Cancer is the second 
leading cause of death in United States exceeded only by heart disease, with an estimate of 1.6 
million new cases and 571,950 deaths in 2011.
29
  Symptoms and signs of cancer depend on the 
type and location of the cancer, but more often the symptoms do not start until the disease has 
reached an advanced stage.  Most cancers are diagnosed by biopsy, and depending on the 
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location of the tumor the biopsy may be simple procedure or a serious operation.   So an efficient 
cancer detection technique needs to develop which can diagnose the disease at an early treatable 
stage.  The principal treatment approach followed these days is surgery; if the tumor is accessible 
and/or chemotherapy and radiation therapy that can eradicate the tumors located deep inside the 
body.
28
  Both chemotherapy and radiation therapy suffers from their non-specific mode of 
actions leading to adverse side effects.
30-33
  For example, the most common chemotherapeutic 
agents such as paclitaxel and doxorubicin exhibit anti-cancer effects by inducing apoptotic death 
of rapidly dividing cells, but they can also kill several types of normal cells that divide rapidly in 
ordinary circumstances.
34-37
  Since the current chemotherapy is mainly based on a whole-body 
treatment with the chemotherapeutic agents, it is inevitable to cause many dangerous side effects 
associated with the non-selective cytotoxic effect of the medications.  Thus, drug delivery in 
cancer is important for optimizing the effect of drugs and reducing the toxic side effects.  
Significant advances have been made in the treatment of many cancer subtypes, but the therapies 
currently available, lack the patient compliance.
38
  The National Cancer Institute (NCI) launched 
the alliance for nanotechnology in cancer for improving cancer mortality defined the path of 
opportunities in the following areas:
39
 
1. Research tools that makes it possible to rapid identification of new biological targets for 
clinical developments. 
2. Agents that can monitor predictive molecular changes to identify precancerous cells and 
prevent them from becoming malignant. 
3. Imaging agents and diagnostics that can allow clinicians to detect cancer in the earliest, 
most easily treatable, pre-symptomatic stage. 
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4. Multi-functional targeted systems that can deliver multiple therapeutic agents directly to 
cancer cells. 
5. Systems that can provide real-time assessments of therapeutic and surgical efficacy. 
6. Novel methods that can manage the symptoms that reduce quality of life 
The use of nanocarriers as DDS for anticancer therapeutics has great potential to 
revolutionize the future of cancer therapies.  In addition nanocarriers with imaging agents offer 
opportunities to exploit optical imaging or magnetic resonance imaging (MRI) for cancer 
imaging and guided hyperthermia therapy.
40
  Inorganic nanoparticles have emerged as viable 
candidate as imaging, diagnostics and sensing agents for cancer treatments.
41
  The nano sized 
metal and semiconductor nanoparticles possess unique electronic, optical and catalytic properties 
that very significantly from the properties of their bulk counterparts.  Nanoparticles based on 
gold, semiconductor metals and iron oxide have been extensively studies as imaging and 
diagnostic agents.
40
  When applied to biological systems this metallic nanoparticles have the 
potential to improve the imaging techniques such as X-ray imaging, near infrared (NIR) imaging, 
position emission spectroscopy (PET) and magnetic resonance imaging (MRI).  Metallic 
nanoparticle probes can enhance the signal sensitivity, and spatial resolution thereby improving 
the sensitivity of the imaging techniques.  Of all the metallic nanoparticles, the focus has been on 
iron oxide nanoparticles due to their biocompatible nature and their superparamagnetic property.  
These iron oxide nanoparticles are responsive to externally applied electromagnetic radiations 
and will produce heat by magnetic hysteresis and will be discussed in detail in chapter 3.  In this 
dissertation the focus would be on the encapsulation of the iron oxide nanoparticles with the 
active agent into a polymer matrix of choice.  The encapsulated nanoparticles can be inductively 
heated by hyperthermia principals to obtain enhanced drug release profiles. 
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1.5.  Nanocarriers for cancer imaging and therapy 
The use of drug delivery systems (DDS), composed of a nanocarrier and its active agent 
(imaging and therapeutic agent), dramatically changes the physicochemical properties of the 
drug as well as its bio-distribution.  It is particularly relevant in the case of very active drugs 
whose use in the clinic has been limited due to their toxicity on vital organs such as heart, 
kidneys, bone marrow and it may also provide new delivery options for the existing drugs 
available.  The most common examples of nanocarriers are prodrugs, dendrimers, liposomes, 
micelles, hydrogels, carbon nanotubes, implantable systems, and polymeric composites.
42-48
  
Figure 1-4 shows the different types of nanocarriers used as drug delivery systems. Nanocarriers 
have the potential to improve the therapeutic index of the drug by increasing the drug payload 
within the carrier and achieve desired drug release, there by reducing the drug toxicity.  
Nanocarriers can also improve the solubility and stability of the drug, allowing a higher drug 
payload. 
Prodrugs are pharmacological substances that are administered in the inactive form and 
are metabolized in vivo into the active form.
49,50
  Prodrugs are used when the drugs have 
unattractive physiochemical properties.  They are generated through the chemical conjugation of 
an active agent with a carrier molecule, which could be a polymer or lipid.  Dendrimers are 
highly branched macromolecules of very small size, and mono-distributed molecular weight that 
can be used to deliver high payloads of drugs through conjugation of the active agent with the 
numerous surface or interior functional groups.
51-53
  The term originates from ‘dendron’ meaning 
a tree in Greek.   Dendrimers are generally prepared using either a divergent method or a 
convergent one.  Both prodrugs and dendrimers have the disadvantage of chemically modifying 
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the active agent, possibly affecting its in vivo activity.
53-56
  Liposomes are artificially prepared 
vesicles consisting of vesicles formed by phospholipids bilayers, and which deliver the drug into 
cells by fusing with cellular membranes.
48,57,58
  Liposomes can be prepared by disrupting 
biological membranes, for example by sonication.  Micelles consist of self-assembled vesicles 
formed by lipids or other amphiphilic molecules (including polymers), which can be used for 
encapsulation and isolation of hydrophobic molecules from the surrounding hydrophilic 
physiological environment.
47,59,60
  A typical micelle in aqueous solution forms an aggregate with 
the hydrophilic "head" regions in contact with surrounding solvent, and the hydrophobic "tail" 
regions in the micelle center.    Liposomes and micelles offer advantages such as prolonged 
circulation time, altered pharmacokinetics, and the ability to encapsulate highly hydrophobic 
drugs, but do not usually provide controlled release over time.
61-64
  Hydrogels are materials 
capable of uptaking significant amounts of water and swelling in result to changes in the 
surrounding environment, resulting in increased pore sizes that allow controlled release of its 
contents.
65,66
  Drug delivery systems based on hydrogels have been shown to result in low drug 
burst effects, but do not usually provide long term drug release.
62
  Carbon nanotubes are 
allotropes of carbon (graphene) with a cylindrical shape.
67,68
  Carbon nanotubes have many 
structures, differing in length, thickness, and in the type of helicity and number of layers. 
Although they are formed from essentially the same graphite sheet, their electrical characteristics 
differ depending on these variations.  Carbon nanotubes in higher concentrations can interact 
with the body fluids and alter the function of the immune systems.
69-71
   Implantable systems can 
provide long term drug release, but require invasive interventions for implantation and removal, 
thus resulting in lower patient acceptability.
72,73
  Polymeric composites encapsulate drugs in 
either a reservoir or matrix arrangement, in which the drug is either localized to the center of the 
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particle and surrounded by a polymer layer, or dispersed throughout a polymeric matrix, 
respectively.
74,75
   Polymeric nanocomposites have shown advantages over nanocarriers in term 
of stability, storage, desired drug release kinetics, toxicity and in-vivo activity. 
 
Figure 1-4: Types of nanocarriers 
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1.6. Polymeric composites 
Polymeric composites are attractive for medical purpose due to their relatively large 
functional surface which can carry, bind or absorb other chemical materials like drugs, proteins, 
genes, and imaging probes.
43,44
   Depending on the conformation, and on the material used to 
fabricate the polymeric composites various drug release kinetic profiles including constant (zero-
order) release can be obtained by the combined effects of drug diffusion and polymer 
degradation.   Polymeric composites can be classified into nano-composites and micro-
composites based on their sizes.  The micro-composites range in diameter from 1 to 250μm, 
while the nanocomposite ranges between 10 to 1000nm.  Polymeric composites can be 
synthesized from number of different natural and synthetic polymers.
76
 Some of the naturally 
occurring polymers used are dextran, cellulose, chitosan.
76
  Synthetic polymers used for 
composite synthesis are poly (methyl methacrylate) (PMMA), poly (styrene-co-vinylbenzyl 
chloride-co- divinyl benzene) (PSVBDVB), polylactic acid (PLA), poly glycolic acid (PGA), 
poly (lactic-co-glycolic acid) (PLGA)
76-78
. Non-biodegradable synthetic polymers like PMMA, 
PSVBDVB are used for synthesizing composites but are not suitable for in-vivo applications as 
they need to be removed surgically.
79
  The polyesters like PLA, PGA, and PLGA are approved 
by Food and drug administration (FDA) for human applications due to their biodegradability, 
biocompatibility, and lower toxicity and will be discussed in detail in chapter 5.
28,78
     Polymeric 
composites, in addition, because of their small size, are able to circulate through capillaries, 
preferentially escape into tumor tissue because of the enhanced permeability and retention effect 
(EPR), and may be taken up by cells for intracellular drug delivery, and will be discussed in the 
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“targeted drug delivery” section. It is these properties of nanoparticles that have been exploited 
for the development of the targeted delivery system in this project.   
1.7. Preparation of Polymeric nanoparticles 
Polymeric composites can be prepared either by directly from the monomers by 
conventional polymerization processes or can be fabricated from the pre-synthesized polymer.  
The conventional polymerization approach uses the monomer as the starting point.  Precipitation 
polymerizations and emulsion polymerization are some of the examples of conventional 
polymerization approach.
76,79,80
  The preparation of the polymeric composites from the pre-
synthesized polymers can be achieved by techniques such as emulsification solvent evaporation 
technique, salting out, spray drying, and nanoprecipitation to name some.
78,81-84
  The selected 
method determines the characteristics of nanocomposites, including the size, as it the most 
important property because it is strongly related to the administration mode.
85
  Another property 
influenced by the preparation process is the ability to interact with active principles contained in 
the drugs formulation.  As a consequence, a deep knowledge of the experimental parameters like 
the solvents, temperature, kind of stabilizer, and stirring rate involved in each method are crucial 
and can bring on the characteristics change in the resulting composites. 
1.7.1. Precipitation polymerization 
Precipitation polymerization is a type of conventional approach for the preparation of the 
nanocomposites.   Precipitation polymerization is a heterogeneous polymerization process that 
starts with a homogeneous system in the continuous phase, where the monomers and initiator are 
completely soluble, but upon initiation the formed polymer is insoluble and thus precipitates 
outs.
79
 
86
  After precipitation of the polymer the polymerization continues with the adsorption of 
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the monomer and initiator on the surface of the formed polymeric particle leading to the growth 
of the particle.  Encapsulation of the active agent (therapeutic agent/ imaging probe) can be 
achieved by adding it along with the monomer initiator assembles.  In this technique it is difficult 
to obtain control over the size and morphology of the formed nanocomposites. 
1.7.2. Emulsion polymerization 
Emulsion polymerization is also a type of conventional approach used for the preparation 
of composites.  Emulsion polymerization is a type of radical polymerization where in the 
polymerization process starts within the emulsion formed by the monomer, initiator and water.
86-
88
  Encapsulation of the active agent can be achieved by adding it along with the monomer 
initiator assembles.   Polymerization is initiated by diffusion of a free-radical into the emulsion.  
The monomers continuously diffuse from the aqueous phase into the emulsion droplets.  Due to 
the small dimensions of the droplets, diffusion of another free-radical into the droplets leads to 
quick termination as a result of coupling of the free-radicals. Thus, the polymerization occurs via 
a single growing chain.  Hence, the molecular weight of the polymer bead can become very high 
before termination.
87,88
 
1.7.3. Emulsification solvent evaporation technique 
Emulsification solvent evaporation is the most promising technique employed for the 
preparation of polymeric nanocomposites. The method is based on the emulsification of an 
organic solution of the polymer in an aqueous phase followed by the evaporation of the organic 
solvent.
89-91
  The polymer is dissolved in a suitable solvent such as ethyl acetate, chloroform, 
methylene chloride.  The organic phase or aqueous phase is poured into the continuous phase 
(aqueous or organic phase) to form the emulsion, which is stabilized by dissolving a surfactant 
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into the continuous phase.   Emulsification is carried out under high-shear stress to reduce the 
size of the emulsion droplet which is directly related with the final size of the nanocomposites.  
The process of emulsification is followed by evaporation of the organic solvent under vacuum, 
which leads to polymer precipitation and nanoparticle formation. This method has two 
alternatives depending on the nature of the active agent to be entrapped within the 
nanocomposites: normal emulsions-oil-in-water (o/w) and double emulsions-water-in-oil-in-
water (w/o/w) techniques.
90
   
1.7.3.1. Oil-in-water emulsion technique: 
The technique is based on the emulsification of an organic solution containing the 
polymer and the active component in an aqueous phase, followed by the evaporation of the 
organic solvent.  Different surfactants such as poly vinyl alcohol (PVA), sodium dodecyl sulfate 
(SDS) or Pluronic F68 can be dissolved in the aqueous phase to stabilize the emulsion formed. 
The size reduction of the emulsion droplet is done by sonication or homogenization to achieve 
nanosized composites.  The evaporation step is required to eliminate the organic solvent present 
in the organic phase and leads to the precipitation of the polymer as nanocomposites with a 
diameter in the nanoscale range.  This technique is suitable for considerable number of 
hydrophobic agents that are soluble in variety of water immiscible solvents and, are poorly 
soluble in water.  Figure 1-5 represents the schematic representation of the oil-in-water 
emulsification technique.  Important parameters to be considered for the o/w emulsion are: 
molecular mass and the concentration of the polymer used, co-polymer ratio and end groups 
employed to functionalized the polymer, type and concentration of the surfactant used, phase 
ratio, solvent nature, evaporation rate, drug entrapment, additives used, and the shear stress 
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applied.
92
  o/w emulsion technique has been employed to prepare the PLGA nanocomposites in 
this project and will be discussed in depth in the following chapters. 
 
 
Figure 1-5: Schematic representation nanocomposite preparation by oil-in-water emulsion 
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1.7.3.2.Double emulsion (w/o/w) technique 
Double emulsion technique is most often used to encapsulate hydrophilic compounds.  
The initial step of the double emulsion technique is the formation of water-in-oil (w/o) emulsion.  
The hydrophilic agent is dissolved in small volume of aqueous phase and this is emulsified in an 
organic phase containing the polymer.  The w/o emulsion formed is further dispersed into larger 
volume of aqueous phase to form the double w/o/w emulsion.
93,94
  The w/o/w emulsion formed is 
sonicated or homogenized for droplet size reduction.  The size reduction carried out under strong 
shear stress has to be carried out carefully to minimize the hydrophilic drug diffusion to the 
external aqueous phase.  The final step is the evaporation of the organic solvent which is carried 
out under vacuum to avoid polymer and component damage.  The important parameters that 
need to be considered are: type and concentration of the polymer used, surfactant nature, 
polymer/surfactant ratio, solvents used, shear stress applied, evaporation and most important the 
ratio of the first/second phase. 
The main drawback of the double emulsion technique is the large particle size and low 
entrapment efficiency of the drug.
93,95
  The mechanism responsible for the poor entrapment 
efficiency is the diffusion of the hydrophilic active agent through the organic phase.  Also, the 
application of intense shear stress may cause degradation of the drug component.
93
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1.7.4.Salting out technique 
 
Figure 1-6: Schematic representation of nanocomposites preparation by salting out 
technique 
 
In the salting out technique the polymer of choice and the active component are dissolved 
in water miscible solvents such as acetone, ethyl acetate or tetrahydrofuran.  This organic 
solution is emulsified under vigorous mechanical stirring in an aqueous phase containing high 
concentration of the salting out agent and the colloidal stabilizer.  This o/w emulsion is diluted 
with sufficient volume of water, under mild stirring.  This reduces the ionic strength of the 
solution leading to the diffusion of the water miscible solvent into the aqueous phase, inducing 
the nanocomposites formation.  The final step is the purification by cross-flow filtration to 
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remove the salting out agent.
96,97
  Common salting out agents used are electrolytes like sodium 
chloride, magnesium chloride or magnesium acetate and non-electrolytes like sucrose.
96
  Figure 
1-6 represents the schematic representation of the salting out technique for nanocomposite 
preparation.   Important parameters to be considered are: molecular mass and concentration of 
the polymer used, mechanical stirring rate and time, nature of surfactant use, nature of the 
salting out agent used, type of water miscible solvent. 
The main drawback of the salting out technique is the requirement of and added 
purification step for the removal of the salting out agent used which is in high concentrations.  
Also the salts used are at times not compatible with the active agents.  Furthermore, this 
technique is suitable for the encapsulation of the lipophilic drugs only.
98
 
 
1.7.5.Nanoprecipitation technique 
In the nanoprecipitation technique the polymer and the active agent are dissolved in a 
water miscible organic solvent such as acetone or ethyl acetate.  The organic phase is then 
slowly poured in a controlled manner into an aqueous phase containing the surfactant such as 
PVA or poloxamer 188 under mild stirring.  Nanocomposites are instantaneously formed due to 
immediate reduction of the interfacial tension with rapid diffusion of the water miscible into the 
aqueous phase.  The organic solvent is removed by evaporation and the nanocomposite 
suspension is concentrated under reduced pressure, centrifuged and freeze dried to obtain 
nanocomposites.
99,100
  Important parameters to be considered are:  polymer concentration, 
nature of the surfactant used, polymer/surfactant ratio, nature of the solvent used, and the phase 
addition.
100
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 Nanoprecipitation technique is only suitable for hydrophilic agents because of their poor 
interaction with the polymer which leads to a considerable leakage of the drug into the aqueous 
phase during preparation.  Also, the active agent to be encapsulated needs to be highly soluble in 
the polar solvent and slightly soluble in water.
101
 
1.7.6. Spray drying 
 
Figure 1-7: Schematic representation of nanocomposite preparation by the spray drying 
technique 
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Spray drying technique enables the transformation of feed from a fluid state into dried 
particulate form by spraying the feed into a hot drying medium. It is a continuous particle 
processing drying operation as shown in Figure 1-7. The feed can be a solution, suspension, 
dispersion or emulsion. The dried product can be in the form of powders, granules or 
agglomerates depending upon the physical and chemical properties of the feed, the dryer design 
and final powder properties desired.  Large batch sizes are typically required as compared to 
emulsion techniques; therefore spray drying technique is often problematic. 
 
 
1.8. Targeted drug delivery of the polymeric nanocomposites to the tumor 
sites 
There are several targeting strategies that can be used to concentrate nanocomposites 
selectively at tumor sites by exploiting differences between malignant and normal cells.   The 
two main drug targeting strategies employed are- passive targeting and active targeting.
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1.8.1. Passive targeting: 
Passive targeting takes advantage of the anatomical difference between the normal and 
tumor tissues to deliver the drug at the tumor site.   As the tumor grows (~2mm in diameter) the 
normal tissues are displaced.  The growing tumor activates the angiogenic process, to generate 
new blood vessels towards the tumor to supply oxygen and nutrients.  The newly formed tumor 
blood vessels vasculature is very different from normal blood vessels, as they are dilated, 
irregular in shape and leaky or defective due to poorly organized endothelial cells.
21
 The 
disorganized pathology of angiogenic tumor vasculature with a discontinuous endothelium leads 
to hyperpermeability to circulate the nanocomposites and lack of effective tumor lymphatic 
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drainage leads to subsequent accumulation of the nanocomposites.  This increased permeability 
of the tumor vasculature is the key feature in passive targeting of the nanocomposites.  This is 
popularly known as enhanced permeability and retention effect (EPR) which results in the 
accumulation of macromolecular drugs and polymeric nanocomposites at the tumor site and 
thus increasing the drug concentration.
3,102
  By taking the advantage of the EPR effect the DDS 
can progressively but selectively build up within the tumor cells and deliver drugs with higher 
drug concentrations compared to the normal cells.  Figure 1-8 illustrates the enhanced delivery 
of the drug through the ERP effect with less normal cell targeting.  
Localized delivery is another approach in which the drug loaded nanocomposites can be 
directly delivered to the target site thus minimizing the circulation of the drug and lowering 
toxicity.
25
  This method is only suitable for the tumors that are easily accessible. 
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Figure 1-8: Illustration of the passive targeting approach with enhanced delivery of the 
drug to the tumor site due to the ERP effect 
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1.8.2. Active targeting: 
 Active targeting strategy exploits the specific binding affinities of targeting 
ligands that are bound to the nanocomposite system used to bind to the target site receptor 
functionalities, thereby allowing preferential accumulation of the drug within the tissue or 
cells.
3,18,102
  This strategy also takes the advantage of the EPR effect for the accumulation of the 
nanocomposites into the interstitial fluid of the tumor and is illustrated in Figure 1-9.  The main 
parameter to be kept in mind is the proper selection of the targeting agent, which should be 
available in abundance, should have high affinity and selectivity of binding to the cell surface 
and should be apt to chemical changes on conjugation.  The identity and characteristics of the 
targeting agent are also important for longer circulation time, cellular uptake, affinity, and 
removal of the nanocomposite.  Therefore, a specific binding capacity of the targeting agent to 
tumors is essential in the success of the drug delivery system.  An increased site specificity and 
internalization can improve the efficacy of treatment and decrease the possibility of the serious 
side effects.  Ligands such as antibodies, saccharides, aptamers, hormones, lectins and low 
molecular compounds  binds to their specific receptor on the cellular surface and trigger the 
internalization process of the drug by means of receptor-mediated endocytosis (REM).  Surface 
receptors like folate receptor (FR), the transferrin receptor (TfR) and the epidermal growth factor 
reseptor (EGRF) have been highly investigated for site specific targeting.
103-105
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Figure 1-9: Active targeting strategy for the delivery of drugs through ligand-receptor 
interaction. 
1.9. Folate receptor 
Folic acid (FA) also known as folate or vitamin B9 is a low molecular weight (MW-441) 
water soluble vitamin required by all living cells for nucleotide biosynthesis and for normal 
metabolic maintenance of 1-carbon pathways.    Cellular uptake of folates are facilitated by 
either a low affinity reduced folate carrier which is present in virtually all cells of the body, or a 
28 
 
high affinity folate receptor (FR) which exhibits highly limited distribution within the body 
cells.  The folate receptor is a 38 kDa glycosyl-phosphatidylinositol-anchored glycoprotein that 
has the affinity for both folic acid and folate linked cargos. 
106
  Two membranous forms of FR-
alpha (α) and beta (β) have been identified.  Both α and β forms have high FA binding affinity, 
however they display some difference with respect to their affinity for antifolates.
107,108
 The 
reduced folate carrier is selective in facilitating transport of reduced forms of folic acid only 
while the FR has the ability to transport both folic acid and folate-linked cargos.  Once the 
folate linked cargos are conjugated to the cell surface FR they are internalized into the cells 
through a process called receptor-mediated endocytosis.  
 
Figure 1-10: Structure of Folic acid 
It has been found that FR is up-regulated in more than 90% of non-mucinous ovarian 
carcinomas. It is also found at high to moderate levels in kidney, brain, lung, and breast 
carcinomas while it occurs at very low levels in most normal tissues.   The FR density also 
appears to increase as the stage of the cancer increases.
18,106
   In addition, folic acid is required 
for essential cell function, therefore the cargo attached to the ligand are retained within an 
endocytic vesicle.  While, the cargos attached to antibodies, hormones, and other related ligands 
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are normally internalized to clear the ligand from the receptor.  Exploiting the above-mentioned 
facts, it can be hypothesized that folic acid conjugation to polymeric nanocomposites will 
improve drug selectivity and decrease negative side effects.     Folic acid has emerged as an 
attractive ligand for drug targeting due to its low molecular size, which allows for good tissue 
penetration. The structure of folic acid (FA) is shown in Figure 1-10.  Also folic acid can be 
easily attached to the polymeric composites through carbodiimide chemistry and will be 
discussed in detail in chapter 6. 
1.10. Summary of Objectives 
 The overall goal of this dissertation work is to develop and design a novel controlled 
release drug delivery system (DDS) with imaging and therapeutic capabilities.   The polymeric 
coating used helps reduce the toxicity of the active agent.  Some of the main objectives of this 
dissertation work are: 
1. Study the synthetic variation upon encapsulation of the magnetic iron/iron oxide 
nanoparticles by synthetic polymer.  Also, study the dilution effect of the saturation 
magnetization of the iron/iron oxide nanoparticles due to the polymer coating. 
2. Develop nano sized mono-dispersed biodegradable poly (lactic-co-glycolic acid) (PLGA) 
composites containing the iron/iron oxide nanoparticles as dual modal imaging and 
therapeutic drug delivery carrier. 
3. Study the release of the drug analog from the magnetic polymeric composites upon 
heating due to magnetic hyperthermia phenomenon with electromagnetic radiations. 
 
        
   
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2. Characterization techniques 
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2.1. Introduction 
The characterization of the synthesized nanomaterials is a very important stage for the 
advancement of quality scientific research.  From the development of the nanomaterial’s 
synthesis technique to the quality control testing of the already established techniques, 
characterization of the nanomaterial is essential.  The characterization of the material aids in the 
precise identification of phases, size, morphology, material impurities, and surface chemistry 
effects of the material.  Characterization of the nanomaterials synthesized plays an important role 
in the scientific research development; hence this chapter will be focused on some of the 
principal characterization techniques used in this research work.   
Characterization technique Application 
X-ray Diffraction (XRD) 
Phase Composition, crystal shape and 
crystallite size 
Scanning electron microscopy (SEM) and 
Transmission electron microscopy (TEM) 
Nanomaterial size and morphology 
Thermogravimetric analysis (TGA) 
Mass change in materials associated with 
dehydration, decomposition, and oxidation 
Vibrating sample magnetometry (VSM) 
Magnetic property and corecivity 
measurements 
Fluorescence spectroscopy Track (bio-) chemical reactions 
Fourier transform infrared spectroscopy (FTIR) Functional group analysis 
Ultraviolet-visible spectroscopy (UV-vis) 
Characterization and quantitative 
determination of analytes 
 
Table 2-1 Principal characterization techniques used 
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2.2. X-ray Diffraction (XRD)  
X-ray powder diffraction (XRD) is an instrumental technique that is used to identify 
crystalline materials and it is a fast and a reliable tool for material identification.  X-rays are 
electromagnetic radiation with energies in the range of 100 eV - 100 keV.  For diffraction 
applications, only short wavelength x-rays (hard x-rays) in the range of a few angstroms to 
0.1˚A are used.  As the wavelength of x-rays is equivalent to the size of atoms, they are ideally 
suited for probing the structural arrangement of atoms and molecules in a wide range of 
materials. The energetic x-rays can penetrate deep into the materials and provide information 
about the bulk structure.  X-rays primarily interact with electrons in the atoms.  When x-ray 
photons collide with sample, a portion of the beam will be scattered in all directions from the 
material and constructively interfere in distinct directions based upon the symmetry of the 
repeating crystal structure associated with the sample material.  The angle where the peaks in 
the x-ray diffraction spectrum occur is given by Bragg's law (Eq.2.1):  
nλ=2d(hkl)sinθ                                                                                                           2.1                                                                                                               
Where λ is the wavelength of the x-ray beam, d(hkl) is the spacing between the (hkl) 
crystallographic plane contributing to the diffraction peak, θ is the angle of incident x-ray, and n 
is an integer for the order of reflection.  This phenomenon creates diffraction patterns as you 
scan the incident angles, which are typically reported and graphed as 2θ.  This diffraction 
patterns have been calculated and experimentally tabulated into data bases for easier matching 
and sample crystal structure determination.   Figure 2-1 represents the diffraction of the x-rays by 
plane of atoms.  It is important to note that the d-spacing provides a unique fingerprint of the 
sample materials under investigation.   
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Figure 2-1: Diffraction of the x-rays by plane of atoms 
 
The primary application of XRD is to investigate the structural nature of the material, for 
example, the size and crystallinity of the sample material.  A material’s structural nature can be 
crystalline or amorphous.  In crystalline materials a higher degree of constructive interference 
will occur, thereby producing sharp constructive diffraction lines in the XRD pattern.  While in 
amorphous materials there are edges, mild distortions, and finite crystalline planes that will cause 
a broadening affect in the diffraction pattern.  There are many factors that may also contribute to 
the broadening of diffraction lines, for example, instrumental broadening, micro-strain (lattice 
strain), powder inhomogeneity, and temperature. Broadening in the diffraction pattern can also 
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occur with a reduction in particle or crystallite size. Peak width due to crystallite size varies 
inversely with crystallite size. So as the crystallite size gets smaller, the peaks get broader. Paul 
Scherrer, first observed that small crystallite size could give rise to peak broadening. He derived 
a well-known equation for relating the crystallite size to the peak width, which is called the 
Scherrer formula (Eq.2.2) 
 (  )  
  
     
                                                                                                            2.2 
For this equation, λ is wavelength of the incident x-ray and θ is the angle of the incident 
x-ray obtained from the center of the diffraction peak, B refers to the peak width, typically 
referred to as the full width at half maximum (FWHM) of the diffraction peak, L the crystallite 
size and K is the Scherrer constant, typically 0.94 for spherical particles with cubic symmetry.  
The Scherrer equation is limited to nano-scale particles and is not applicable to grains larger than 
about 0.1 μm.  A small impurity in a sample is enough to overwhelm the diffraction pattern and 
gives a size value much larger than would be representative of the majority of the sample in 
question.  This is a major reason that other particle size determining methods such as TEM, SEM 
are required for nanomaterials research.  Another reason for utilizing other size determining 
methods is that only crystalline materials are apparent in the XRD diffraction pattern.  This 
means that amorphous regions, say on the surface of nanoparticles would not be included in the 
sizes determined by XRD.  Also band broadening becomes a major factor in nanoparticles 
research.  Even for crystalline materials, once below 5-10 nm the diffraction pattern peaks appear 
more as broad humps than spikes.  As the peaks broaden it becomes more difficult to separate the 
background, sample, and impurities. 
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Figure 2-2: Schematic representation of the X-ray diffractometer 
 
Figure 2-2 shows the schematic of the θ: θ x-ray diffractometers. In the θ: θ x-ray 
diffractometers the sample is stationary in the horizontal position, and the X-ray tube rotates at a 
rate -θ°/min and the detector rotates at a rate of θ °/min.   The other type of x-ray diffractometer 
is θ: 2θ in which the X-ray tube is stationary, the sample moves by the angle θ and the detector 
simultaneously moves by the angle 2θ.  The drawback of θ: 2θ x-ray diffractometer is that at 
high values of θ small or loosely packed samples may have a tendency to fall off the sample 
holder.  In the commercial x-ray diffractometer the X-rays are generated from an X-ray tube 
under vacuum when the filament within the tube is heated by the application of a current. The 
numbers of electrons emitted from the filament are directly related to the amount (voltage) of the 
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applied current. The high voltage accelerates the electrons towards a target, typically made of 
copper or molybdenum; the wavelength of the X-ray is dependent on the type of the target. Next, 
these x-rays are directed towards the finely ground sample and finally, the detector detects the 
signal which will be processed either electronically or by microprocessor to a count rate.   
For the purposes of this work, powder X-ray diffraction (XRD) was taken on a 
Panalytical X’pert pro diffractometer.  A copper anode was used as the source of x-rays with a 
current of 45 mA at an accelerating voltage of 40 kV. As described previously, the copper source 
emits x-rays with Kα1 and Kα2 wavelengths of 1.540 ˚A and 1.544 ˚A respectively.  The dried 
powder samples were gently ground using a mortar and pestle and then pressed onto a zero 
background, low volume silicon sample holder. The sample holder was then placed in the 
instrument for XRD analysis. Upon completion of the run, the data were analyzed in the 
Highscore plus program, which has a built-in diffraction library to compare the samples 
diffraction pattern to the diffraction patterns in the JCPDS-ICDD database.    XRD was used for 
phase identification, identifying the purity of samples, and determining the crystallinity of 
products.   
2.3. Scanning electron microscopy (SEM) 
Scanning electron microscope (SEM) uses a focused beam of high-energy electrons to 
generate a variety of signals at the surface of solid sample. The signals derived from electron- 
sample interactions reveals information about the sample including external morphology 
(texture), chemical composition, and crystalline structure and orientation of materials making up 
the sample.  The combination of higher magnification, larger depth of focus, greater resolution, 
and ease of sample observation makes the SEM one of the most heavily used instruments in 
research areas today. 
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Figure 2-3: Schematic of the main components of SEM 
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Figure 2-3 shows a schematic of the main components of the SEM.  The electron beam, 
which typically has an energy ranging from 0.5 keV to 40 keV, is focused by one or two 
magnetic lenses to a spot about 0.4 nm to 5 nm in diameter. The beam passes through pairs of 
scanning coils or pairs of deflector plates in the electron column, which deflect the beam in the x 
and y axes so that it scans in a raster fashion over a rectangular area of the sample surface.  The 
electron beam interacts with the sample and emits out a variety of signals.  These signals include 
secondary electrons (SE) which are emitted from the surface as they are knocked out of the 
valence orbitals of the surface atoms, backscattered electrons (BSE) which are scattered off the 
surface, and photons (characteristic X-rays that are used for elemental analysis and continuum X-
rays) as depicted in Figure 2-4 
  The secondary electrons are used to create an image of the surface, which has a 3D 
quality as the angle of the secondary electron projection depends on the angle of the incoming 
beam. Thus steep surfaces and edges tend to be brighter than flat surfaces, which results in 
images with a well-defined 3D appearance. A backscattered electron profile is also collected as 
the number of backscattered electrons increases with atomic number, so atoms of a higher atomic 
number appear brighter in the image.  The photons are produced by inelastic collisions of the 
incident electrons with electrons in discrete orbitals (shells) of atoms in the sample. As the 
excited electrons return to lower energy states, they yield X-rays that are of a fixed wavelength.  
Thus, characteristic X-rays are produced for each element in sample material that is "excited" by 
the electron beam. The SEM is routinely used to generate high-resolution images of shapes of 
objects and to show spatial variations in chemical compositions.  Precise measurement of very 
small features and objects down to 50 nm in size can be accomplished using the SEM.  Also the 
SEM analysis is considered to be "non-destructive"; that is, x-rays generated by electron 
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interactions do not lead to volume loss of the sample, so it is possible to analyze the same 
materials repeatedly.  
 
Figure 2-4: Origin and information depth of secondary electrons (SE), backscattered 
electrons (BSE), and x-rays in the diffusion cloud of electron beam into the sample 
 
In this research work the size, size distribution, and morphology of the samples were 
determined using Hitachi SU-70 field emission scanning electron microscope (SEM) equipped 
with digital image acquisition, EDX, WDX, EBSP, STEM, BSE, CL detectors.  The morphology 
of the nanomaterial sample is represented in the SEM image by dark and grey areas.  The 
contrast is due to the interaction of the electron beam with the sample.  The SEM samples are 
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prepared by lightly sprinkling the powdered sample on a conductive carbon tape mounted on the 
sample holder.  The sample is then lightly pressed to seat and then sprayed with canned air to 
remove any loose sample from top.  The sample was then sputtered with gold to make it 
conductive and reduce charging.  Charging is a buildup of excess of electrons (charge) on the 
surface of the non-conductive sample, which causes an undesired electron beam deflecting 
leading to an increase in the brightness of the image.  The sample holder is then placed in the 
sample compartment of the microscope and the images are obtained as described above. 
SEM can provide precise resolution around ±50 nm and has ±200,000 X resolution 
power, but for nanoparticle research higher resolution up to few angstroms is desirable.  For this 
purpose transmission electron microscopy (TEM) is utilized which has a resolution around ± 0.2 
nm.  Both TEM and SEM utilize electron beams to detect the size and morphology of sample 
materials.  In a SEM image is produce from electrons detected after scattering off the surface of 
the sample where as in a TEM image is produced by electrons passing through the sample placed 
on a grid.  The electron density of the solid nanomaterial sample scatters some of the electrons, 
with the remaining electron beam passing by to produce a silhouette of the material on a screen 
for imaging. The TEM image provides information about the size, shape, size distribution, and 
uniformity.  Also the core-shell nature of the nanomaterial sample can also be determined by the 
difference in the electron density. High resolution TEM can see lattice fringes and can be used 
for electron diffraction which will give insight into the crystal structure similar to XRD.  In this 
work the TEM was performed on Carl Zeiss Libra 120 Plus Field Emission Transmission 
Electron Microscope (TEM) to evaluate the size and morphology of the synthesized 
nanoparticles. 
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2.4. Thermogravimetric analysis (TGA) 
Thermogravimetric analysis (TGA) is an instrumental technique where in the mass of the 
sample in a controlled atmosphere is recorded continuously as a function of temperature or time 
as the temperature of the sample is increased linearly with time.  The thermogravimetry 
instrument consists of a sensitive analytical micro balance, furnace, purge gas system for 
providing an inert atmosphere and a computer and processor for instrument control and data 
recording.  Figure 2-5 represents the schematic representation of the components of a thermal 
gravimetric balance. 
TGA provides quantitative measurement of mass change in materials associated with 
transition and thermal degradation. TGA records change in mass from dehydration, 
decomposition, and oxidation of a sample with time and temperature.  The most important 
application of thermogravimetric technique is found in the study of polymers.  Thermograms 
provide information about the decomposition mechanism for various polymers.  Also the 
uniformity in the polymer can be known.  A tactic polymer would have fewer number of 
decomposition events as compared to an atactic polymer.   The application of TGA in 
nanomaterial research is to determine the amount of organic ligands/impurities that are adsorbed 
onto a nanoparticle surface formed during the synthesis procedure.  This percentage of organics 
associated with the total mass of the nanoparticle is important information for magnetization 
mass correction as it is dependent on the mass of the magnetic material and not the total mass of 
the system.   It also provides information about the mass percentage of the organics in the 
sample.  This information can give indication of how well a surface is coated with a functional 
ligand, and in some way give insight to the surface area to volume ratio of the sample. 
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Figure 2-5: Block diagram of the Thermogravimetric analyzer 
 
TGA also offers an easier way of annealing samples where in the sample size is critical.  
This use may not be as common, but has the advantage of working with smaller sample size than 
a traditional heating furnace, such as a tube furnace.  It also allows for the monitoring of mass 
loss of a sample under different gaseous atmosphere.  In this work the thermogravimetric 
analysis was performed on a TA instruments Q5000 thermogravimetrtic analyzer.  The sample is 
positioned on a platinum pan that is supported on an analytical balance which located outside the 
furnace chamber. After the balanced is zeroed, the sample is heated and the weight signal is 
stored as a function of temperature and time. 
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2.5. Vibrating sample magnetometry (VSM) 
The vibrating sample magnetometer is an analytical instrument employed for determining 
magnetic properties of a large variety of materials: diamagnetic, paramagnetic, ferromagnetic, 
ferromagnetic and antiferromagnetic. This experimental technique was invented in 1956 by 
Simon Foner, a scientist of the MIT.  A vibrating sample magnetometer (VSM) operates on 
Faraday's Law of Induction, which states that a change in magnetic field will produce an electric 
field. This electric field can be measured and provides information about the changing magnetic 
field.  As shown in Figure 2-6  VSM operates by first placing the sample in a constant magnetic 
field.  If the sample is magnetic, this constant magnetic field will magnetize the sample by 
aligning the magnetic domains or magnetic spins with the applied field. If the sample vibrates in 
a sinusoidal motion, an electrical signal can be induced between two coils (pick-up coils) 
according to the Faraday’s law.  This electric signal has the same frequency of vibration and the 
amplitude is proportional to the magnetization of the sample.  The produced current will be 
amplified and then using a computer interface that contains a specific software system, 
information about the magnetization of the sample and its dependence on the magnetic field 
could be obtained. 
The ability to perform measurements at various temperatures is available for the VSM 
but the resolution and sensitivity is not comparable to that of the SQUID, and thus  most of the 
VSM are set up to measure at room.  The main advantage that the VSM offers to material 
research is that the measurements can be done much more quickly than using a SQUID, and do 
not require liquid He.  A Lakeshore model 7300 room temperature vibrating sample 
magnetometer was used determine the magnetic properties of materials in this research work.  
The measuring field was oriented either parallel or perpendicular to the plane of the sample 
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depending on the sample shape i.e. for example pellets were oriented parallel, while powders 
were oriented perpendicular to the magnetic field.  
 
  
 
Figure 2-6: Schematic showing the main components of vibrating sample magnetometer 
(VSM) 
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2.6.Fluorescence spectroscopy 
Fluorescence spectroscopy is a type of electromagnetic spectroscopy where the molecules 
of the sample are excited by irradiation at a definite wavelength of light (usually ultraviolet) and 
emit radiation of lower energy (higher wavelength).  The emission spectrum provides 
information for both qualitative and quantitative analysis.   When light of an appropriate 
wavelength is absorbed by a molecule (i.e., excitation), the electronic state of the molecule 
changes from the ground state to one of many vibrational levels in one of the excited electronic 
states. The excited electronic state is usually the first excited singlet state, S1 (Figure 2-7).  
Collisions with other molecules cause the excited molecule to lose vibrational energy until it 
reaches the lowest vibrational state of the excited electronic state. The molecule then drops down 
to one of the various vibrational levels of the ground electronic state again, emitting a photon in 
the process. As molecules may drop down into any of several vibrational levels in the ground 
state, the emitted photons will have different energies, and thus frequencies.   Fluorescence is 
one of these processes that correspond to the relaxation of the molecule from the singlet excited 
state to the singlet ground state with emission of light.  The wavelength and thus the energy of 
the emitted light are dependent on the energy gap between the ground state and the excited state.  
The fluorescence quantum yield (Φ) gives the efficiency of the fluorescence process. It is defined 
as the ratio of the number of photons emitted to the number of photons absorbed (Eq. 2.3). 
    
  
∑    
                                                                                                  2.3 
Where kf is the rate of spontaneous emission of radiation and ∑iki is the sum of all rates of 
excited state decay. Other rates of excited state decay are caused by mechanisms other than 
photon emission and are therefore called "non-radiative rates", which can include: dynamic 
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collisional quenching, near-field dipole-dipole interaction internal conversion and intersystem 
crossing as shown in Figure 2-7. 
 
Figure 2-7: Electronic transition energy level diagram 
 
In this research work fluorescent dyes Tris-(2,2'bipyridyl)dichlororuthenium (II), 
Rhodamine B were used as the drug analog.  The release of these dyes from the polymeric 
composites was determined using the fluorescence spectroscopy.  Fluorescence spectroscopy is 
recognized as one of the most sensitive technique, and it is possible to measure the concentration 
of the fluorescent substance at nano gram levels.   This work was carried out on Cary Eclipse 
Fluorescence Spectrophotometer equipped with a xenon lamp.  Figure 2-8 represents the 
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schematic representation of the fluorescence spectroscopy.  The light from the xenon source that 
is excited passes through the monochromator and lands on the sample. The sample absorbs a 
portion of the incident light and the fluorescent molecules in the sample emit the light. A 
detector is attached at a viewing angle (usually around 90 degrees), which prevents incident light 
from contaminating the detected fluorescent light. 
 
Figure 2-8: Block diagram of a fluorescence spectroscopy 
 
2.7.Fourier transform infrared spectroscopy (FTIR) 
Infrared spectroscopic technique utilizes lower energy infrared (IR) radiation (10000 – 
100 cm
-1
) to induce vibrational and rotational excitation of atoms and groups of atoms within a 
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molecule.  When the frequency of the incident light equals to resonant frequencies of the internal 
molecular vibrations in a material, absorption occurs causing the molecule to vibrate in a higher 
energy level.  Absorption occurs when the incoming IR radiation that is interacting with a 
molecule has sufficient energy to raise the vibrational energy level of the molecular system to the 
next allowed level.  The frequencies and intensities of absorbed infrared light depend on the 
specific bond strengths and the geometrical shapes of the molecule.  The absorption pattern 
(called a spectrum) is unique for each material.  The infrared spectrum is measured by either 
absorbance or percent transmittance on the y-axis and by either the wavelength (μm) or 
wavenumber (cm
-1
) to measure the position of an infrared absorption on the x-axis.  Analysis of 
this absorption spectrum reveals details about the molecular structure of the sample based on the 
known symmetric and random vibrational modes of different atomic arrangements.  This can be 
very helpful in functionalization studies for scientific research. For example, the shifting or 
disappearance of absorption bands in the spectrum of a given functional ligand can be evidence 
to change in the functional group of the ligand.  Although this technique does not typically give 
conclusive evidence alone, it can be very powerful if used in conjunction with other data. 
The main component in the FTIR spectrometer is an interferometer.  The interferometer 
consists of two mirrors and a beam splitter positioned at an angle of 45 degrees to the mirrors 
which separate it into two beams. One will reflect from a fixed mirror in place and the other will 
reflect from a moving mirror.  The two beams are then reflected back and recombined at the 
beam splitter with half of the light passing on toward the sampling areas and half travelling back 
toward the source. The signal at the detector is a cosine wave. 
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Figure 2-9: Block diagram of FTIR spectrometer 
 
 Fourier transform infrared (FTIR) spectroscopy was performed with Thermo Nicolet 
NEXUS 670 FTIR attached to an attenuated total reflectance (ATR) accessory.  ATR was fitted 
with a single bounce diamond at 45° internally reflected incident light providing a sample area of 
1 mm in diameter with a sampling depth of several microns.  This accessory provides for the 
non-destructive measurement of samples with little or no preparation.  A small amount of the 
sample was directly placed on the diamond disk and scanned for absorbance over the range from 
4000 to 500 cm
–1
 wave numbers at a resolution of 1 cm
–1
. 
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2.8. Ultraviolet-visible spectroscopy (UV-vis) 
Ultraviolet visible spectroscopy measures the response of a sample to ultraviolet and 
visible radiations region of electromagnetic spectrum.  When the sample is irradiated with light 
with wavelength in the UV-vis region, the molecular atoms undergoes electronic transitions from 
the ground state to the higher excited state.  These electronic transitions in organic compounds 
can be explained by one of the following processes: σ to σ* transition that is present in 
compounds containing single bonds.  π to π* transition that takes place in compounds that 
contain double bonds.  n to σ* and π to π* transitions are present in compounds containing lone-
pair of electrons and a single or a double bond respectively.  Also, d-d or f-f transitions in 
inorganic compounds take place between a ground and an excited state of the d and f orbitals 
respectively.  The wavelength and amount of light that a compound absorbs depends on its 
molecular structure and the concentration of the compound used.   
Figure 2-10 shows the basic setup of the UV-vis spectrometer. A beam of light from a 
visible and/or UV source passing through the diffraction grating where the light is separated into 
its component wavelengths.  Then the monochromatic light beam travels through the aperture, 
which is an opening that determines the cone angle of the light rays that comes to focus in the 
image plane. Finally the light passes through the sample before the materials absorption is 
detected.  In this work UV-vis spectroscopy was used to determine the folic acid conjugation to 
the PLGA polymer.  The UV-vis spectroscopy was performed on Hewlett Packard 8453 UV-
visible Spectroscopy Systems. 
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Figure 2-10: Block diagram of the UV-vis spectrophotometer 
 
        
   
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3. Iron oxide nanoparticles and their properties 
 
 
 
 
 
 
 
 
 
 
 
53 
 
3.1. Iron oxide nanoparticles 
Magnetic iron oxide nanoparticles are iron oxide particles with diameters between 1-
100 nanometers (nm).  There are several different forms of iron oxide; however the three main 
forms in which the iron oxide nanoparticles exist are magnetite ( Fe
II
Fe
III
2O4, ferrimagnetic), 
maghemite (α-Fe2O3, ferrimagnetic), and hematite (γ- Fe2O3, weakly ferromagnetic or 
antiferromagnetic).
109,110
  Magnetite has an inverse spinel structure with the divalent Fe
2+
 ion in 
tetrahedral (A sites) coordination and the trivalent Fe
3+
 ions in octahedral (B sites) coordination 
with oxygen as shown in Figure 3-1.
111
  Maghemite also have an inverse spinel structure like 
magnetite in which each cell contains 32 oxygen ions, 21 1/3 Fe
3+
 ions and 2 1/3 vacancies.
110
  
It differs from magnetite in that all or most of the iron are in the trivalent Fe
3+
 state and cations 
are distributed randomly over the 8 tetrahedral and 16 octahedral sites.  Hematite has a 
rhombohedral crystal structure with the trivalent Fe
3+
 ions in octahedral coordination with 
oxygen.
110
  These nanoparticles can be synthesized using a variety of synthetic techniques such 
as the sol-gel process, reverse micelles technique, chemical precipitation, hydrothermal 
synthesis, polyol technique, and physical vapor deposition, and pyrolysis.
112-117
 All these 
methods are well used procedures for nanoparticles preparation; however, the particles 
produced by these techniques differ in the size, morphology, size distribution and magnetic 
properties.
110,116,118
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Figure 3-1: Drawing of the spinel structure illustrating the octahedral and tetrahedral 
sites 
 
3.2. Magnetism 
Magnetic property in general sense arises from unpaired electron spins in outer shell, or 
valence electrons of an atom.  An Iron atom with 4 unpaired electrons in 3d shell has a strong 
magnetic moment.  Ions Fe
2+
 has also 4 unpaired electrons in 3d shell and Fe
3+
 has 5 unpaired 
electrons in 3d shell. Therefore, when nanoparticles are formed from iron atoms or ions Fe
2+
 
and Fe
3+
 they can be in ferromagnetic, antiferromagnetic, or ferrimagnetic states.  A better 
understanding of magnetism in general is an essential step on the way into understanding the 
magnetism of these nanoparticles.  The magnetic behavior of materials can be classified into 
five major groups as shown in Table 3-1 
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Types of 
Magnetism 
Applied magnetic field Resultant effect 
Diamagnetism 
 
 Repel the field 
 Negative magnetic 
susceptibility 
Paramagnetism 
 
 Align from the field 
 Small positive 
magnetic 
susceptibility 
 
Ferromagnetism 
 
 Align with the field 
 Large positive 
magnetic 
susceptibility 
Antiferromagnetism 
 
 Half of the spins 
align with the field 
 Divergence observed 
in the magnetic 
susceptibility 
Ferrimagnetism 
 
 Some spins align 
with the field and 
some did not 
 Positive magnetic 
susceptibility 
 
Table 3-1: Schematics of the five main types of magnetism seen in a material and their 
response to the applied magnetic field.  Paramagnetic, Ferromagnetic, and Ferrimagnetic 
materials have net positive magnetic moment in the direction of the applied field.  
Diamagnetic and Antiferromagnetic materials have a zero net moment. 
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3.3.Diamagnetism and Paramagnetism 
Diamagnetism refers to materials that are repelled from an applied magnetic field.  
Diamagnetic material has paired electrons in their valence shell, leading to a net zero magnetic 
moment.  When an external field is applied a force is generated by the field that leads to 
speeding up or slowing down of paired electrons.  This leads to the change in the magnetic 
moment of the orbital in a direction opposite to the external field.  The spins in diamagnetic 
materials align in an opposite direction to the field leading to negative magnetic susceptibility.   
Paramagentism is the direct opposite of diamagnetism which takes on an alignment in 
the direction of the applied magnetic field i.e. they are attracted to a magnetic field.  In a 
paramagnetic material, the spins of the electrons are not coupled and will have a resultant 
magnetic moment.  This moment tend to align with the applied magnetic field leading to a 
small positive magnetic susceptibility.  Paramagnetic materials have short range magnetic 
order because they relax back to their original random state in the absence of magnetic field.  
The other basic forms of magnetism- ferro, ferric and antiferro magnetism like paramagnetism 
possess magnetic moment.  The only difference to paramagnetic material is in the ability of 
these magnetic materials to interact and couple with the applied magnetic field through 
exchange coupling. 
3.4. Exchange coupling 
Exchange coupling is a quantum mechanical phenomenon arising due to the relative 
orientation of the spins of two electrons.  There are three types of exchange coupling by which 
atomic spins in a material can interact.  These are direct exchange, indirect exchange, and 
superexchange that may produce either parallel or antiparallel exchange coupling.  Direct 
exchange occurs due to quantum mechanical coupling between electrons of adjacent atoms. 
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For example if a system involves two atoms, each with one electron and if the interatomic 
distance is relatively small, the electrons will spend most of their time between the nuclei to 
minimize Coulomb interactions.  Pauli’s exclusion principle states that electrons in the same 
space and time must possess opposite spins, as illustrated in Figure 3-2.  This gives rise to 
antiparallel alignment and therefore negative exchange. 
 
Figure 3-2: Direct exchange coupling between the neighboring atoms leads to an 
antiparallel alignment of the electrons. This is due to Pauli’s exclusion principle when the 
electrons are located in the same space and time. 
 
Indirect exchange coupling takes place when the interatomic distances are larger.  The 
electrons then tend to be away from each other to minimizing electron-electron repulsion. This 
results in the parallel alignment or positive exchange as shown in Figure 3-3. 
 
Figure 3-3: Indirect exchange coupling takes place due to larger interatomic distance 
between the adjacent atoms leads to a parallel alignment 
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Superexchange occurs between two atoms that are too far apart to be connected by 
direct coupling, but are connected by some other nonmagnetic atom, such as oxygen. Fig. 3.4 
shows a simple representation of superexchange between two spins connected by a common 
nonmagnetic atom.  Parallel or anti parallel alignment of the coupled electrons is dependent on 
the distance and orientation or bond angles of the exchange.  For example, the tetrahedral sites 
in the spinel ferrite structure align anti-parallel to the octahedral sites via this superexchange 
mechanism.  The metal cations in the ferrites and metal oxides interact through superexchange. 
 
Figure 3-4: Superexchange between two magnetic atoms through a nonmagnetic atom 
 
3.5. Ferromagnetism, Ferrimagnetism and Antiferromagnetism 
Ferromagnetic materials exhibit parallel alignment produced due to indirect coupling of 
the electron spins.  The electron spins in ferromagnetic materials align parallel to each other 
within small regions of the material to form domains. In an un-magnetized state, the domains 
are aligned at random so there is no overall magnetic effect. When an external magnetic field is 
applied to the material, the domains align to point in the same direction, producing a strong 
overall magnetic effect.  Ferromagnetic materials tend to have long range ordering and show 
high positive magnetic susceptibility.  While in antiferromagnetic materials the magnetic 
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moments of atoms that are related to the spins of electrons, align in opposite direction to each 
other due to direct exchange coupling.  Antiferromagnetic materials have zero net 
magnetization as the magnetic moments equal in magnitude are aligned in opposite directions.  
Ferrimagnetic materials magnetic moment is aligned antiparallel to each other as in 
antiferromagnetic materials but the moments are unequal in magnitude and spontaneous 
magnetization remains.  The substances behave like ferromagnetic materials.  Ferrimagnetism 
is exhibited by ferrites and magnetic oxides. 
Figure 3-5 represents the curve of the magnetization (alignment of the spins with 
magnetic field) versus the applied field curve, commonly known as the M-H curves of 
diamagnetic, paramagnetic, and ferromagnetic materials.  Diamagnetic materials show an 
inverse relation between the applied field and the magnetization because the spins oppose the 
direction of the applied field.  While a direct relationship between the applied field and the 
magnetization is seen for paramagnetic materials as their spins align with the field.  As the 
paramagnetic materials have short range magnetic ordering, no saturation magnetization (Ms) 
is observed.  Saturation magnetization (Ms) is described as the alignment of all the spins of the 
particles with the applied external magnetic field.  Consequently they have zero remnant 
magnetization (Mr) and zero corecivity (Hc).  Remnant magnetization (Mr) is the retention of 
magnetization in the absence of an applied magnetic field and zero coercivity (Hc) is defined as 
the intensity of the applied magnet field required to reduce the magnetization of that material to 
zero after the magnetization of the sample has been driven to saturation.  The M-H curves for 
ferromagnetic forms a hysteresis loop.  High magnetization saturation is reached in 
ferromagnetic materials as the magnetic domains align with the applied field.  Thus, 
ferromagnetic materials have a coercivity value higher than zero, because a certain amount of 
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energy is needed to randomize the highly aligned domains.   They also retain magnetization 
after the applied field is removed giving a positive remnant magnetization value. 
 
Figure 3-5: The expected plot of magnetization vs. applied field for diamagnetic, 
paramagnetic and ferromagnetic materials 
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3.6. Superparamagnetism 
In bulk ferromagnetic materials, when an external magnetic field is applied the 
magnetic moments exhibit multi domain properties, each domain presents a group in which all 
the atomic magnetic dipoles are spontaneously aligned.  These magnetic domains are separated 
by domain walls of ~100 nm width.  When the bulk magnetic materials are reduced to 
nanoscale the width of the domain walls also reduces.  Magnetic particles below a certain 
diameter cannot support more than one domain and are thus described as single-domain.
119
 
This diameter is termed as the critical diameter and is given by Eq. 3.1 
  
 
 
  
                                                                                                                                 3.1 
Where A is the exchange constant, MS is the moment per unit volume and for typical 
materials its value is 10–50 nm.119   At this size all the atomic magnetic moments are rigidly 
aligned as a single giant spin and the magnetic behavior of the particles is defined as 
superparamagnetism.
117,119,120
  When a high magnetic field is applied however, the spins align 
with each other resulting in saturation of the magnetic moment (similar to ferromagnetism), but 
when the magnetic field is removed, the magnetic moments undergoes magnetic relaxation 
(similar to paramagnetism).  The relaxation of the magnetization orientation of each particle is 
determined by Eq. 3.2 
    
      
                                                                                                          3.2  
Where τ is the relaxation time at one orientation, K is the particle’s anisotropy constant, 
Vis the particle volume, k is the Boltzmann’s constant, and T is the temperature. As the size of 
the particle decreases to a level where KV (free-energy barriers) becomes comparable to kT 
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(thermal energy), its magnetization starts to fluctuate from one orientation to another, leaving 
no coercivity and net magnetic moment.
119,121
  At this nanoscale the particle responds quickly 
to an external magnetic field to reach saturation magnetization, while dropping back to zero 
when the field is removed.   
This superparamagnetic property of the iron oxide nanoparticles makes them very 
attractive for potential applications in several fields, especially for biomedical applications 
such as enhanced  resolution magnetic resonance imaging (MRI), targeted drug delivery and 
imaging, hyperthermia, magneto-transfections, gene therapy, stem cell tracking, 
molecular/cellular tracking, magnetic separation technologies (e.g. rapid DNA sequencing), 
detection of liver and lymph node metastases.
122-124
  The focus of this research is on designing 
a dual modal imaging and therapeutic drug delivery system, so the role of superparamagnetic 
iron oxide nanoparticles as contrast agents in MRI and heating agents in hyperthermia will be 
discussed briefly in sections 3.3 and 3.4. 
3.7. Magnetic resonance imaging (MRI) application 
Magnetic resonance imaging (MRI) is a powerful tool for the diagnosis of disease and 
the study of biological processes such as cancer metastasis and inflammation.  MRI makes use 
of the property of nuclear magnetic resonance (NMR) to image hydrogen nuclei inside the 
body.  The MRI image is constructed because of the difference in the rates of equilibrium 
states of protons that are present in various environments (tissues).  The protons in water and 
tissue will align in a given direction (z-axis) when a static magnetic field is produced by the 
MRI magnets.   A radio frequency (RF) pulse at the resonance frequency (Larmor frequency) 
is applied to the aligned protons which flips the spin of the aligned protons in the body.  Once 
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the Rf pulse is removed the excited protons begin to relax back to their original spin states 
through longitudinal relaxation time (T1) or transverse relaxation time (T2).  The spin lattice or 
longitudinal relaxation time (T1) describes the rate that nuclear spins return to equilibrium and 
the spin–spin or transverse relaxation time (T2) is the time constant that describes the rate of 
signal decay.  The MRI signal is governed by the concentration of protons and the nuclear 
relaxation time, T1 and T2.
125
  The image contrast can be varied by adjusting the instrumental 
parameters of the imaging process or by taking advantage of the intrinsic parameters such as 
the local concentration of the hydrogen nuclei, relaxation parameters, and magnetic 
susceptibility.  Above all this the contrast of the image can be enhanced by intravenously 
injecting contrast agents.
126,127
  MRI contrast agents alter the relaxation times of the tissues and 
body cavities, and depending on the image weighting, it can give a higher or lower contrast 
signal.  Paramagnetic gadolinium (Gd) based particles are the most commonly used MRI 
contrast agents, which shows a strong T1 shortening effect.
128
  However they have relatively 
low contrast effects and a very short retention time in vivo.  Also the toxicity and 
biocompability of these Gd based contrast agents are not clearly known.
129
   
Superparamagnetic iron oxide (Fe3O4 and Fe2O3) nanoparticles are gaining much attention as 
MRI contrast agents. 
123,130,131
   Superparamagnetic iron oxide nanoparticles have high 
magnetic moment which can cause microscopic field inhomogeneity and can activate the 
dephasing of the protons.  This makes them effective in reducing the T2 relaxation time, and 
thereby leading to signal hypo- intensities in T2  or T2
*
 weighted images.  The image areas 
containing iron oxide nanoparticles therefore induce a signal darkening on the MRI 
images.
109,132
  The signal void due to the large magnetic susceptibility of the nanoparticles is 
much larger than the nanoparticle size, thus enhancing the detectability.  Designing these 
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nanoparticles with targeting specificity, the negative contrast alterations can be harnessed to 
report abnormal biological activity.   
3.8. Magnetic hyperthermia 
 Hyperthermia can be defined as controlled temperature elevation by targeting the 
heating field to the malignant tumors as well as the surrounding tissue, organ, part of body or 
even to the whole body.  The use of hyperthermia in the treatment of malignant tumors is well-
known since ancient times.  Hippocrates, the father of medicine had proposed that surface 
tumors can be treated by the application of hot iron.
133
  Hyperthermia is a promising form of 
cancer therapy alongside of the typical methods of surgery, chemotherapy and radiotherapy.  
Hyperthermia takes the advantage of the cancerous cells being more sensitive to higher 
temperatures in the ranged of 42-45º C than the healthy cells.  The tumor cells could be killed 
by necrosis if the temperature is above 45º C, or could it can help improve the efficiency of 
chemotherapy if the temperature is raised around 42º C.
134
 
Magnetic iron oxide nanoparticles act as mediators and help induce heat to the tumors.  
When these nanoparticles are exposed to an external alternating current (AC) magnetic field, 
some heat is generated due to magnetic hysteresis loss.  These losses, depending upon the 
thermal conductivity and heat capacity of the surrounding medium are dissipated in the form of 
heat; raising the temperature of the surrounding.  The amount of heat generated depends on the 
nature of the magnetic particles and the external field applied.  The heat dissipated by a 
magnetic nanoparticles subjected to an AC magnetic field is given by specific absorption rate 
(SAR), which is described as shown in Eq. 3.3.  SAR is expressed in W/g of nanoparticles. 
      
  
  
                                                                                                                3.3 
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Where C is the specific heat capacity of the sample and T and t are the temperature and 
time, respectively.
135,136
  SAR is very sensitive to the material properties.  In multi-domain 
particles the heat is generated mainly due to magnetic hysteresis loss, but it is different for 
small, single domain particles.  As the size is reduced the particles shows superparamagnetic 
behavior and would not exhibit hysteresis loss.   The two main contributing mechanisms of 
SAR in single domain superparamagnetic nanoparticles are the Néel relaxation and Brownian 
relaxation.  Néel relaxation is the random flipping of the spin without rotation of the 
nanoparticle and depends on the magnetic property of the nanoparticles. The Néel relaxation 
mechanism is analogous to the hysteresis loss in multi-domain magnetic particles whereby 
there is an internal friction due to the movement of the magnetic moment in an applied external 
magnetic field that results in heat generation.  In Néel relaxation the moment alignment occurs 
via the usual Stoner–Wohlfarth process subject to thermal activation where the relaxation time 
is given by Eq. 3.4. 
        
(
  
  
)
                                                                            3.4 
Where τN is the Néel relaxation time, τ0 is the average relaxation time in response to a 
thermal fluctuation and is typically in the order of a few nanoseconds, k is the Boltzmann 
constant, T is the temperature and ∆E is the energy. 
Brownian relaxation is the rotation of the entire nanoparticle within the fluid medium 
and depends on the viscosity of the medium as shown in Figure 3-6.
133,136,137
  In Brownian 
relaxation the moment can align with the ﬁeld by physical rotation with a relaxation time given 
by Eq.3.5 
   
    
  
                                                                                                                 3.5 
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Where η is the viscosity coefficient of the fluid, k is the Boltzmann constant, VH is the 
hydrodynamic volume, T is the temperature, and τB is the Brownian relaxation time. 
 
Figure 3-6: Schematic representation of relaxations of magnetic particles either through 
spin rotation (Neel) or particle rotation (Brownian), when the particles are exposed to an 
AC magnetic field.  Néel relaxation is the random flipping of the spin without rotation of 
the nanoparticle while the Brownian relaxation is the entire rotation of the nanoparticle 
in the fluid. 
 
        
   
 
 
 
 
 
 
 
 
 
 
 
Chapter 4. Poly (styrene-co-vinylbenzylchloride-co-divinylbenzene) 
(PSVBDVB) composites containing magnetic iron oxide 
nanoparticles 
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4.1. Overview 
Polymeric nanocomposites have evolved as a potential tool for the design of an ideal drug 
delivery system (DDS) for cancer treatments.  Both imaging and therapeutic agents can be 
encapsulated within the polymeric nanocomposites through various techniques as discussed in 
chapter 1.  In this project magnetic iron oxide nanoparticles have been used as a dual modal 
imaging (contrast agents for MRI) and therapeutic agent (heat mediators in hyperthermia), which 
are encapsulated into poly (styrene-co-vinylbenzylchloride-co-divinylbenzene) (PSVBDVB) 
polymer.
79
 
The key step in the design of a dual modal drug delivery system is the encapsulation of 
the magnetic iron oxide nanoparticles with polymer of choice.  A proper understanding of 
possible synthetic anomalies that arise from the inclusion of nanoparticles within the polymer 
during synthesis is necessary.  It is also very important to investigate the dilution effect of the 
saturation magnetization of the iron oxide nanoparticles due to the polymer coating.  Different 
types of polymer coating have been investigated and the choice of the appropriate one depends 
on many factors and principally on the clinical purposes of the functionalized nanoparticle. The 
most commonly polymer coating used for biocompatible iron oxide nanoparticles is derivatives 
of dextran.
138,139
  The association of dextran with iron oxide has led to its widespread use as a 
coating for iron oxide NPs for many decades.  However, either dextran or nanoparticles made 
with dextran can cause anaphylactic reactions.  Also the dextran coating is found to be 
biologically unstable and leads to sedimentation and aggregation of the iron oxide 
nanoparticles.
140
  Therefore it is desirable that the magnetic nanoparticles be efficiently 
encapsulated into a robust polymer. 
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To study these synthetic variations upon encapsulation with a polymer, the magnetic iron 
oxide nanoparticles were encapsulated into a robust poly (styrene-co-vinylbenzylchloride-co-
divinylbenzene) (PSVBDVB).
79
   PSVBDVB is a copolymer of styrene, vinylbenzylchloride 
(VB) and divinylbenzene (DVB) and their structures are shown in Figure 4-1.  Polystyrene 
copolymer is biocompatible, cheap, well-known, and can be easily functionalized by 
copolymerization.  Also the polymerization process for the synthesis of polystyrene is very well 
established.
141
  Furthermore the encapsulation of iron oxide nanoparticles within the polymer can 
be carried out by polymerization process, which ensures a homogenous distribution of the 
nanoparticles within the composites.   The cross linking agent divinylbenzene (DVB) was used 
to impart better mechanical strength to the polymeric composites, as compared to styrene alone.  
Vinylbenzylchloride (VB) confers a hydrophilic group to the composites which makes it possible 
for use in a wider range of applications like drug delivery, column separation technique.  The 
only difference to styrene is that VB contains chlorine to the para position to the vinyl group so it 
would not interfere in the polymerization process and good distribution of VB would be 
obtained.  Also addition of VB allows for the functionalization of the magnetic composites at the 
chlorine site through nucleophilic substitution reactions.     
 
Figure 4-1: Structure of styrene, vinylbenzylchloride (VB) and divinylbenzene (DVB) 
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4.2. Synthesis  
The first step in the synthesis of PSVBDVB composites containing the iron oxide 
nanoparticles is the synthesis of mono-dispersed iron oxide nanoparticles.  In order to prepare 
iron oxide nanoparticles with uniform size and shape, it is necessary to control the kinetics of 
their nucleation and growth.  The best control is achieved when the nucleation and growth steps 
are separated.  There are numerous methods of iron oxide nanoparticle synthesis such as co-
precipitation method, polyol technique, reverse micelles technique, sol gel technique, 
hydrothermal synthesis, chemical and physical vapor deposition, and pyrolysis.
114,142-144
  Polyol 
technique is a simpler synthetic technique that allows for the control over the nucleation and 
growth events and will be discussed in detail in section 4.2.1  
The next step is the synthesis of the PSVBDVB composites with iron oxide 
nanoparticles.  To properly understand the possible synthetic anomaly that arises from the 
inclusion of nanoparticles within the polymer during synthesis.  A homogenous polymer coating 
is desirable for magnetic nanoparticle encapsulation.  For this reason precipitation 
polymerization technique was employed for the formations of PSVBDVB composite, where in 
the polymeric composites are synthesized from its monomers.  PSVBDVB as discussed earlier is 
a copolymer of polystyrene.  Conventional methods for the synthesis of the copolymers are 
dispersion polymerization, suspension polymerization, and emulsion polymerization.  Mono-
dispersed sub-micron sized polymeric composites with a highly cross linked structure cannot be 
obtained by these processes.  Precipitation polymerization was thus utilized to synthesize highly 
cross linked polystyrene copolymers.
145,146
  It is a very simple and versatile polymerization 
technique yielding mono-dispersed spherical polymeric composites.  Precipitation 
polymerization will be discussed in detail in section 4.2.2 
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4.2.1. Synthesis of magnetic Iron oxide nanoparticles by Polyol technique 
Iron oxide nanoparticles were synthesized by polyol technique similar to those found in 
the literature.
115,147,148
  The polyol technique refers to the use of a polyalcohol (polyol) to reduce 
the metal precursor.  The polyalcohol used acts as a solvent as well as when coupled with a base 
serves as a mild reducing agent.
115
  In this technique, a solid inorganic precursor is suspended in 
a liquid polyol along with a base.  The suspension is stirred and heated to a given temperature, 
leading to super-saturation of the solution.  Consequently a short nucleation burst will occur 
followed by a slow growth of the metallic particles.
115
  The starting materials can range from 
metal hydroxides, nitrates, chlorides to acetates. The reduction of metal precursors can be 
achieved in various polyols such as ethylene glycol, propylene glycol, diethylene glycol, 
trimethylene glycol, butylene glycol, and trimethylene glycol.  The polyol technique produces 
finely dispersed, non-agglomerated metal nanoparticles with well-defined morphology, narrow 
size distribution and high crystallinity.  The main advantage of polyol technique over other 
synthetic routes is that the polyol solvent also act as a protective layer preventing particles 
aggregation and passivates the nanoparticles against oxidation. 
The synthesis of the iron oxide nanoparticles was carried out by polyol technique as 
shown in Figure 4-2.   0.40 g of Iron (II) acetate was slowly added to 25.00 mL ethylene glycol 
under magnetic stirring.  After the metal precursor was completely dissolved 1.00 g of sodium 
hydroxide (NaOH) was added and the reaction solution was quickly heated to reflux under 
magnetic stirring for 1 hour. The initial reddish-brown solution turned black at the end of 1 hour 
reflux.  The iron oxide nanoparticles were then magnetically extracted and further washed 
several times with methanol.  In order to prepare the particles for the polymerization coating 
process, two further washes and extractions were performed with anhydrous acetonitrile and 
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sonication to remove any surface water, methanol, or glycol.  After the last acetonitrile wash, the 
particles were dried in a vacuum oven and kept under vacuum until further use. 
 
 
Figure 4-2: Synthesis of Iron oxide nanoparticles by Polyol technique 
4.2.2. Encapsulation of magnetic iron oxide nanoparticles with in the Poly (styrene-co- 
vinylbenzylchloride-co-divinylbenzene) (PSVDVB) composites 
Precipitation polymerization was carried out by similar methods used to produce poly 
(styrene-co-divinylbenzene) microspheres with the addition of vinylbenzylchloride in place of 
some styrene monomer.
141,149
  Precipitation polymerization technique is a heterogeneous 
polymerization process that starts with a homogeneous system in the continuous phase, where 
the monomers and initiator are completely soluble, but upon initiation the formed polymer is 
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insoluble and thus precipitates outs.
150
  During polymerization, the growing polymer chains 
phase-separate from the continuous medium by entropic precipitation as the cross-linking 
prevents polymer and solvent from freely mixing.
151
  The uniqueness of precipitation 
polymerization is the absence of polymeric stabilizer which is the key element in other 
polymerization processes.  The PSVBDVB composites containing iron oxide nanoparticles were 
synthesized as below. 
 Styrene and divinylbenzene (DVB) monomers were treated with 0.10 M sodium 
hydroxide solution to remove the inhibitor.   Vinylbenzylchloride (VB) and azobisisobutyronitril 
(AIBN) were used as received.  AIBN is used as an initiator for the polymerization process to 
start.  The polymer composites were synthesized with monomer percentages of 30% styrene, 
25% vinylbenzylchloride, and 45% divinylbenzene as shown in Figure 4-3.  The iron oxide 
nanoparticles were added to 1.00 mL of monomer solution at mass percentages of 0%, 1%, 3%, 
and 5%, which was then placed under sonication to achieve a homogeneous dispersion of the 
particles in the monomer solution.  The monomer solution or the particle/monomer solution was 
taken in a 250 mL round bottom flask equipped with a reflux condenser under N2 atmosphere, 
and then 50.00 mL of anhydrous acetonitrile was added as the solvent.  The reaction mixture was 
stirred mechanically at the rate of 60 rpm.  Then 20.00 mg of AIBN (initiator) was added to the 
reaction solution and the solution was heated to 75°C to initiate the polymerization process.  
Once the temperature was stabilized at 75°C, the reflux condenser was capped with a balloon to 
maintain the reaction under N2, and the reaction was allowed to age for 24 h.  The reaction was 
then quenched in “cold” methanol (~-20ºC) to precipitate the spherical polymeric composites. 
Vacuum filtration was employed for the polymeric composites without the magnetic 
nanoparticles and magnetic separation was employed for iron oxide nanoparticle loaded 
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polymeric composite samples followed by further drying under vacuum to obtain the final 
product.  
 
Figure 4-3: Structure of Poly (styrene-co-vinylbebzylchloride-co-divinylbenzene) along 
with its monomer content 
 
4.3. Result and discussion 
The PSVDVB coated magnetic iron oxide nanoparticles were characterized using a 
variety of analytical techniques including scanning electron microscopy (SEM), thermal 
gravimetric analysis (TGA), X-ray powder diffraction (XRD), and vibrating sample 
magnetometer (VSM). 
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Scanning electron microscopy (SEM) was performed on the polymeric composites, with 
and without the magnetic iron oxide nanoparticles loading.  The SEM samples were prepared by 
lightly sprinkling the composite powder on a conductive carbon tape mounted on the sample 
holder.  The sample was then sputtered with gold to make it conductive and reduce charging.  
The PSVBDVB composites without the iron oxide nanoparticle loading were spherical and 
mainly mono dispersed and had a mean diameter of 3 μm as seen in Figure 4-4 (a).  With 
addition of 1% iron oxide nanoparticles by mass a decrease in the size of the polymeric 
composites to a mean diameter of 2 μm was observed, as well as an increase in the poly-
dispersity of the composites was seen as shown in Figure 4-4 (b).  With further increase in the 
ratio of iron oxide nanoparticles the size of the polymeric composites decreases and poly-
dispersity of the composites increases.  The difference in these samples can be explained if the 
particles act as nucleation sites for the polymer chains.  In the case without particles, the number 
of polymer chains should be somewhat proportional to the amount of initiator.  Then with a 
uniform amount of chains being connected by cross-linker (DVB), uniformly sized composites 
are achieved.  When the nanoparticles are added, this gives a site for the monomers and forming 
polymer chains to orient or nucleate.  This causes the DVB cross-linking agent to be used more 
quickly because the polymer chains are closer together, especially since the DVB has been found 
to be more reactive than the styrene monomer in the typical polymer synthesis.
152
  It also uses 
more monomers around the surface of the nanoparticles due to their high surface area, thus 
shortening the overall length of the polymer.   
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Figure 4-4: (a) SEM image of as synthesized polymer beads without nanoparticle, (b) 1% 
by mass nanoparticle to polymer reaction 
 
Figure 4-5: Histograms of size measurements from SEM images of nanocomposites with 
varying nanoparticle loading percentages. 
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This trend in size reduction is seen to continue as more nanoparticles are added to the 
system.  The diameters of the spheres obtained are 3 ± 0.15 μm for 0% nanoparticles, 2 ± 0.30 
μm for 1%, 1 ±0.35 μm for 3%, and 0.5 ± 0.15 μm for 5%, and are shown in Figure 4-5.    
 
Figure 4-6: TGA plot showing decomposition profiles for the nanocomposites and polymer 
beads 
 
Thermal gravimetric analysis (TGA) was used to investigate the composition of the 
composites formed.  The PSVBDVB composites without the iron oxide nanoparticle loading 
show a major decomposition event around 350 ºC corresponding to the decomposition of the 
PSVBDVB copolymer.  As can be seen in Figure 4-6 the 0% loaded sample has a smooth 
decomposition profile with one primary decomposition temperature around 350 ºC.  As the 
nanoparticle loading is increased to 1%, the first major decomposition event is observed around 
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440º C which is indicative of higher levels of cross linking between the monomers or greater 
density copolymer formation.  There is also an addition decomposition event at around 720º C 
that is not present in the unloaded PSVBDVB composites and is attributed to the decomposition 
of the sample impurities on the surface of the iron oxide nanoparticles.    Increasing to 3% 
nanoparticles loading the decomposition profile is similar to 1%, with slight differences in the 
later decomposition event around 700º C again attributed to decomposition of sample inpurities 
on the surface of nanoparticles..  Then upon increasing to 5% loading, a third decomposition 
event is observed at around 500º C attributed to the decomposition of the high density 
PSVBDVB copolymer.  The increase in the decomposition temperature and the decomposition 
events is observed with increase in the nanoparticles loading.  As the nanoparticle loading 
increases, DVB is used up quickly as the nucleation sites increases. This causing a non-uniform 
composition polymer formation due to the rapid utilization of the monomers, which is evident 
from the difference in the decomposition profiles.   
The powder XRD pattern of the as-synthesized iron oxide nanoparticles shows an inverse 
spinel iron oxide phase with no impurities.   Figure 4-7 shows XRD patterns of the as-
synthesized iron oxide nanoparticles with an overlay of the data obtained from the JSPDS 
reference powder diffraction patterns of maghemite (α-Fe2O3).  By comparing the reference 
diffraction pattern to the collected data, it is clear that the raw data is a representation of 
maghemite.    The most intense peaks at 30.266º, 35.651º, 43.33º, 50.044 º, 53.766º, 57.319º, 
62.949º, 71.430º, 74.493º 2θ corresponds to the (220), (311), (400), (421), (422), (511), 
(440),(620), and (533) planes in the maghemite crystal structure.  The peaks were indexed by the 
JCPDS database for maghemite (p4332, card#01-089-5892) 
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Figure 4-7: XRD pattern of the as-synthesized iron oxide nanoparticles with an overlay of 
the data obtained from the JSPDS reference powder diffraction pattern of maghemite. 
 
Magnetic characterization was performed by vibrating sample magnetometer (VSM) to 
confirm that the composites synthesized were indeed magnetic and that the magnetization of iron 
oxide nanoparticles was retained post polymerization. Figure 4-8 shows a hysteresis plot of the 
as synthesized iron oxide nanoparticles and the composites with 5% nanoparticles loading, both 
measured at room temperature. As can be seen, the saturation magnetization of the iron oxide 
nanoparticles was 62 emu/g and is considered high since bulk maghemite has a magnetization 
saturation range of 80-100 emu/g.  The saturation magnetization of the iron oxide nanoparticles 
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after polymerization was 6 emu/g and the reduction in the saturation magnetization is due to the 
magnetic dilution due to the polymeric coating.   Utilizing the TGA data for mass correction of 
the polymer composite sample yielded a magnetization of 60 emu/g of iron oxide in the sample.  
This shows that the iron oxide nanoparticles remained unchanged during the polymerization 
process and no significant change is observed on the magnetization of the nanoparticles.  Both 
samples showed a coercivity of roughly 10 Oe at room temperature.   
 
Figure 4-8: Plot of magnetization vs applied field for the as synthesized iron oxide 
nanoparticles and the nanocomposite synthesized with 5% loading of the iron oxide 
nanoparticle 
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4.4.Conclusion 
These results discussed indicates that the iron oxide nanoparticles are not just 
incorporated into the polymer matrix but act as nucleation sites for the polymerization process to 
begin.  Although the polymerization process was found to have no effect on the magnetization of 
the nanoparticles, the nanoparticles had several effects on the resultant polymer composites size 
and morphology by decreasing the diameter, increasing the polydispersity, and decreasing the 
uniformity of the polymer composition.  These effects of nanoparticle loading reported give 
insight into parameters that may need to be adjusted in order to obtain similar polymer sizes, 
composition, and mechanical properties as nanoparticle loading is increased.   
The encapsulation of magnetic iron oxide nanoparticles in the PSVDVB polymer was 
achieved, but the magnetic PSVDVB composites cannot be utilized for drug delivery 
applications.  PSVDVB polymer is a non-biodegradable polymer.  The polymeric composites if 
introduced parenterally in the body will need to be surgically removed as the polymeric 
composites will not disintegrate within the body.
153
  Due to its non-biodegradability the 
PSVDVB composites are not suitable for drug delivery applications.  Thus, there is a need of a 
robust biocompatible and biodegradable polymer that can be used for biomedical purposes and 
will be discussed in chapter 5. 
But the PSVBDVB composites with iron oxide nanoparticles can be used for cell 
separations and as adsorbent for chromatography.
154-156
  These application of polymer coated 
iron oxide nanoparticles will be discussed in chapter 7. 
        
   
 
 
 
 
 
 
 
 
 
 
Chapter 5. Poly (D, L-lactide-co-glycolide) microcomposite containing 
magnetic iron core nanoparticles as a drug carrier 
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5.1. Overview 
An appropriate selection of the polymer matrix is necessary in order to develop a 
successful drug delivery system.  The polymer can be non-biodegradable or biodegradable.  But 
as discussed earlier the major disadvantage with non-biodegradable polymers is that a surgery is 
required to harvest these polymers out of the body once they are depleted of the drug.  Hence, 
non-degradable polymers can be used only if removal of the implant is easy.
153
  On other hand 
biodegradable polymers either synthetic or natural, are capable of being cleaved into 
biocompatible byproducts through chemical or enzyme-catalyzed hydrolysis.
157,158
 This 
biodegradable property makes it possible to inject them into the body without the need of 
subsequent removal by the surgical operation.
153
  Drug delivery systems formulated with these 
polymers can be released in a controlled manner, by which the drug concentration in the target 
site is maintained within the therapeutic window.  Biodegradation of polymeric biomaterials 
involves cleavage of hydrolytically or enzymatically sensitive bonds in a polymer, leading to 
polymer erosion.   The erosion of the polymer matrix is usually classified into two categories: 
bulk (or homogeneous) erosion and surface (or heterogeneous) erosion.
159
  Bulk erosion occurs 
when the rate at which water penetrates into the polymer exceeds the rate at which the polymer is 
converted into water soluble materials (monomers), resulting in erosion.
160
  The size of the 
polymeric composites remains almost constant in bulk erosion.   While surface degradation 
occurs when the rate at which the polymer penetrates the device is slower than the rate of 
conversion of the polymer into water soluble materials as shown in Figure 5-1.
160
  The rate of 
degradation of biodegradable polymers is dependent on their hydrophilicity, and on the 
accessibility of their hydrolytic unstable bonds to water and to specific enzymes that can break 
these chemical bonds.  Consequently, the water uptake capability of the material, its 
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morphology, crystallinity, and molecular weight are key parameters that determine the 
degradation kinetics of the polymer. 
 
Figure 5-1: Schematic representation of bulk and surface erosion.  In bulk erosion the 
degradation takes place throughout the polymer surface, while surface erosion results in 
the thinning of the polymeric particle. 
 
5.1.1. Natural polymers 
Early research into biodegradable polymeric DDS was mainly focused on naturally 
occurring polymers like the proteins such as collagen, gelatin, and albumin and polysaccharides 
such as glucose, dextran, starch,  and chitosan.
161
  The chemical structures of naturally occurring 
polymers are shown in Figure 5-2.  The application of proteins for drug delivery has been limited 
due to their low mechanical stability and high cost.  On the contrary polysaccharides have 
attracted researchers as they are commercially available at low cost and can be modified by 
simple chemical reactions for specific applications.  Chitosan a type of polysaccharide has been 
85 
 
much researched as it has shown excellent biocompability, biodegradability, low 
immunogenicity and biological activity.  These naturally occurring polymers mostly undergo 
degradation through enzymatic bond cleavage.   
 
Figure 5-2: Chemical structures of naturally occurring biodegradable polymers 
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5.1.2. Synthetic polymers  
Recently the research focus into biodegradable polymeric DDS has shifted on to synthetic 
polymers as they offer the advantage of tailoring the degradation process.  For synthetic 
polymers, passive hydrolysis is the primary mode of degradation.  In case of degradation by 
hydrolysis, bulk degradation takes place and can be controlled by applying control over the rate 
of water penetration and material swelling, which is governed by the hydrophilicity of the 
polymer.
162,163
 Some of the synthetic polymer used for DDS are poly(ortho esters) (POE), 
polyanhydrides,  polyphosphazenes, and aliphatic polyesters.
161
   
 
Figure 5-3: Chemical structures of the four generations of poly(ortho)esters (POE) 
 
Poly(ortho)esters (POE) have evolved through four generation as biodegradable polymers 
and their structures are shown in Figure 5-3.
164
  However, only the third and fourth generations 
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POEs are semisolid and suitable for the manufacturing of a drug delivery system relevant for 
clinical use.  They are easy to manufacture and are characterized by faster degradation rates 
compared to polyesters.
165
  POEs have a degradation span of several days to several months.   
POEs undergo surface erosion because of high hydrophobicity and water impermeability.
165
  In 
POE composites the drug release and surface erosion of the polymer takes place simultaneously. 
Polyanhydrides have been investigated for short term drug release as they undergo rapid 
degradation in vivo and have poor mechanical properties.
166,167
  Their main advantage is that they 
contain the most reactive anhydride groups available for degradation.   Polyanhydrides are 
known to also undergo surface erosion and their degradation rate can be manipulated by varying 
the polymer composition.
168
  The main drawback of these polymers is that they need to be kept 
frozen under anhydrous conditions because of the dynamic hydrolysis of the anhydride bond.  
Polyanhydrides have a degradation spam of few days to few weeks. 
Polyphosphazenes are liner polymers composed of an inorganic backbone with nitrogen 
and phosphorous atoms.
169
  These polymers can be modified readily by manipulating either the 
backbone or the side chain, thus enabling the tuning of their degradation rate.  These polymers in 
presence of water cleave into nontoxic, low molecular weight products such as phosphates, and 
ammonia.  Polyphosphazenes can degrade by both bulk and surface erosion depending on the 
accessibility of the bonds and hydrophobicity of the polymer.
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Aliphatic polyesters with hydrolysable backbones are promising candidates for control 
release DDS.  This class of polymers degrades via the hydrolytic cleavage of the ester bonds in 
their backbone.  While the role of enzymatic degradation for this class of polymers is not clearly 
understood.  Some of the widely used aliphatic polyesters are poly(lactide) (PLA), 
poly(glycolide) (PGA) and the copolymer of PLA and PGA- poly (lactide-co-glycolide) (PLGA) 
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and their structures are shown in Figure 5-4.  These polymers have been used in biomedical 
applications for more than 20 years and are known to be biodegradable, biocompatible and non-
toxic, and are approved by FDA (Food and Drug Administration) for human applications. 
 
Figure 5-4: Chemical structure of polyesters 
  
Poly(lactide)  and Poly(glycolide) are polymer formed by ring opening polymerization of 
lactic acid and glycolic acid respectively.
171
  They both belong to the α-hydroxy polymer family 
and degrade by the hydrolysis of the ester linkage to produce the respective monomers- lactic 
acid and glycolic acid.  Both of these polymers have been extensively researched as appropriate 
candidates for drug delivery matrixes.  PLA has three forms due to the presence of a chiral center 
D(-), L(+), and racemic (DL) forms.   PGA degrades easily as it is more hydrophilic in nature 
due to the absence of the methyl groups while on other hand PLA is found to be more robust in 
the body.
172
    PLA takes the longest to degrade biologically, with a biodegradation time of more 
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than two years while PGA biodegrades relatively quickly, in only two to three month.  Because 
these polymers vary differently in the biodegradation time, their copolymers can be synthesized 
with a wide-variety of degradation times, depending on the application. 
5.2. Poly (lactide-co-glycolide) (PLGA) 
Poly (lactide-co-glycolide) (PLGA) is a copolymer of lactide and glycolide, and is 
synthesized by random ring opening co-polymerization process.  Commonly used catalyst for the 
co-polymerization process are tin(II)2-ethylhexanoate, tin(II) alkoxides, and aluminium 
isopropoxide.  In the co-polymerization process the monomers- lactide and glycolide are linked 
together by ester linkage yielding a linear, amorphous PLGA polymer as shown in Figure 5-5. 
 
Figure 5-5: Ring opening co-polymerization process of lactide and glycolide in presence of 
catalyst to obtain PLGA 
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The forms of the PLGA are identified by the composition of the monomer used such as 
PLGA 50:50 or PLGA 75:25.  The degradation rate and the mechanical properties of the polymer 
can be influence by varying the monomer ratio (ratio of lactide: glycolide) and by controlling the 
monomer stereochemistry, molecular weight, and degree of polydispersity.   For example PLGA 
50:50 has the fastest degradation time of about 50-60 days and likewise PLGA 65:35, 75:25, 
80:20, and 90:10 have progressively longer degradation time.
173
  PLGA undergoes bulk 
degradation through random hydrolysis of the backbone ester linkage in presence of water to 
produce the original monomers.  The degraded monomers- lactic acid and glycolic acid are 
easily metabolized into the body via the Krebs cycle and are eliminated.
174
   Thus there is 
minimal systemic toxicity associated with using PLGA for biomedical applications. Also the 
original shape and mass of the polymer is preserved until 90% degradation has occurred.  The 
general properties and degradation rate of PLGA, PLA and PGA are summarized in Table 5-1. 
Polymer Crystallinity Tg (ºC) 
Degradation 
rate 
PGA 
Highly 
crystalline 
35-40 2-3 months 
PLLA 
Semi-
crystalline 
60-65 ˃ 2 years 
PDLLA Amorphous 55-60 12-16 months 
PLGA Amorphous 45-55 1-6 months 
 
Table 5-1: General properties of the polyester polymers- PGA, PLLA, PDLLA, PLGA and 
their respective degradation rates 
 
PLGA composites can be synthesized by various techniques such as emulsification 
solvent evaporation technique, salting out, spray drying, nano-precipitation techniques as 
discussed in chapter 1.  The emulsion solvent evaporation technique is the most frequently used 
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to produce polymeric composites.  This technique is simplest of all and encapsulation of the 
therapeutic and imaging agent can be carried out with ease.  The physical properties of obtained 
composites are strongly dependent on the nature of materials and also on the parameters during 
the manufacturing of the composites. 
This chapter focuses on the preparation of biodegradable and biocompatible PLGA 
composites for drug delivery applications.
78
  For this work the emulsion solvent evaporation 
technique was used to produce the PLGA composites containing the metallic iron nanoparticles 
and ruthenium dye as the drug analog.  The iron-iron oxide core shell nanoparticles (Fe@FeOx) 
were used as imaging and heating agents as discussed earlier.  Fe@FeOx core shell nanoparticles 
were used instead of iron oxide nanoparticles as they possess superior magnetic properties due to 
the formation of metallic iron core.  The Fe@FeOx core shell nanoparticles were synthesized by 
reverse micelle technique and will be discussed in synthetic section. 
5.3. Tris-(2,2'bipyridyl)dichlororuthenium (II) [Ru(bpy)3]
2+
 dye 
 
Figure 5-6: Chemical structure of Tris-(2,2'bipyridyl)dichlororuthenium (II) [Ru(bpy)] 
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Tris-(2,2'bipyridyl)dichlororuthenium (II) [Ru(bpy)3]
2+
 is a ruthenium based metal 
complex dye, and its structure is as shown in Figure 5-6.  It is a red crystalline salt obtained as a 
hexahydrate.  Ru(bpy) was used as the drug analog, as it is a fluorescent dye so its release from 
the polymeric composites can be easily monitored through fluorescence spectroscopy. In 
aqueous solution the [Ru(bpy)3]
2+
 cation has an excitation wavelength of 470 (±3) nm.  Due to 
the absorption of visible light by [Ru(bpy)3]
2+
 leads to the formation of the charge transfer 
excited state *[Ru(bpy)3]
2+
 as shown in Eq. 5-1 
[Ru(bpy)3]
2+ 
 + hv                        *[Ru(bpy)3]
2+
                                                               5-1                 
 The excited state has a life time of about 890 nano seconds and then relaxes back to the 
ground state by emission of photons at a wavelength of 610 nm as shown in Eq. 5-2. 
*[Ru(bpy)3]
2+
                        [Ru(bpy)3]
2+ 
 + hv’                                                              5-2   
However, if a quencher  is present, the excited state will decay to the ground state more rapidly 
due to the formation of electron transfer  complex.  The reaction can be shown as in Eq. 5-3.
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*[Ru(bpy)3]
2+
 +  Q
(n)+
                       [Ru(bpy)3]
2+
 +  Q*                                                  5-3   
The excited *Ru(bpy)3 can act as both electron donor and electron acceptor species. A 
variety of inorganic and organic species such as metal ions, and oxygen can act as quenchers.
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The efficiency of the electron transfer quenching is governed my factors such as distance 
between the donor and acceptor, degree of quantum mechanical coupling between the molecular 
orbitals of donor and acceptor as well as the free energy change (∆Gº) for the reaction.177,178   
 In this work the fluorescent Ru(bpy) dye was used  as drug analog to study its 
release from the PLGA composites  when irradiated with microwave radiation.  The Fe@FeOx 
nanoparticles quench the fluorescence of the Ru(bpy) dye through charge transfer quenching.  
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The Fe@FeOx nanoparticles and the Ru(bpy) dye are closely packed within the composites so 
the donor acceptor distance is reduced thus increasing the rate of charge transfer.  
5.4. Synthesis 
Iron-iron oxide core shell nanoparticles (Fe@FeOx) nanoparticles were synthesized by 
reverse micelle technique.  Before describing the reverse micelle synthetic technique a brief 
overview of the technique will be provided in section 5.3.1.  The PLGA composites with the 
Fe@FeOx nanoparticles and the dye were prepared by emulsion solvent evaporation technique 
and will be discussed in section 5.3.3.  PolyD,L-lactide-co-glycolide 50:50 i.v (PLGA) was 
obtained from Polysciences, Inc. Poly (vinyl alcohol) (PVA) 88% hydrolyzed with an average 
molecular weight of 88,000 and anhydrous dichloromethane (DCM) were purchased from Arcos 
organics.  Tris-(2,2'bipyridyl)dichlororuthenium (II) [Ru(bpy)3Cl2·6H2O] was purchased from 
Sigma Aldrich.  All chemicals were used as received without further purification 
5.4.1. Overview of Reverse micelle technique 
Reverse micelle technique has been utilized to synthesis the iron-iron oxide core shell 
nanoparticles.  The main advantage of this technique is that the size distribution can be improved 
even in room temperature reactions.  Normally if the reaction is carried out at room temperature, 
the nucleation and growth events compete greatly expanding the size distribution of 
nanoparticles synthesized.  It is also cost effective, fast reaction requiring simple equipment and 
it does not require temperature or pressure control.   The reverse micelles isolate reactants from 
one another, thereby better regulating the nucleation and growth at lower temperatures.  A proper 
understanding of the reverse micelle and the processes involved is essential. 
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Figure 5-7: Schematic representation of water in oil reverse micelle (right) and oil in water 
micelle (left) 
 
Micelles are formed when an oil phase, aqueous phase, and the surfactant are mixed in a 
proper proportion.  The surfactant is required to have an affinity for both the aqueous and oil 
phases, and it acts to provide the barrier between the primarily immiscible phases.  Micelles are 
formed when the concentration of the surfactant exceeds the critical micelles concentration 
(CMC) in water.  There are several types of surfactant used for reverse micelles that can be 
categorized into four groups: cationic, anionic, nonionic and zwitterionic.   In normal micelles 
the surfactant’s hydrophobic tail is directed toward the interior part and the hydrophilic head is 
directed towards the surrounding aqueous phase. Alternatively, in reverse micelles, the 
hydrophilic head of the surfactant is directed towards the interior of the micelles and the 
hydrophobic tail is directed to the oil phase.  Figure 5-7 shows the difference between normal 
micelles (left) and reverse micelles (right).  The reverse micelle droplets that are formed act as 
nano-reaction vessels in which the nanoparticles synthesis can be carried out.  The size of the 
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nanoparticles formed can be controlled by controlling the size of the formed reverse micelles.  
The reverse micelles can also exist as dimers for nanoseconds during which some exchange of 
materials between the micelles takes place allowing for sequential synthesis techniques.
179
  Also 
as the reverse micelle reaction takes place in aqueous media, so variety of chemical reactions 
such as oxidation- reduction, co-precipitation, and substitution reaction can be easily carried 
out.
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5.4.2.Iron-iron oxide (Fe@FeOx) core shell nanoparticles synthesis via reverse micelle 
Iron-iron oxide (Fe@FeOx) core shell nanoparticles were synthesized via reverse micelle 
techniques under nitrogen using Schlenk line techniques as found in the literature.
180,181
   The 
surfactants used for this synthesis were nonylphenoxy poly(ethyleneoxy)ethanols with differing 
head group repeating units of 9 and 5 as surfactant and co-surfactant (NP9/NP5) sold by Rhodia 
Incorporated under the name Igepal CO-520 and CO-630 as shown in Figure 5-8.  Cyclohexane 
was used as the solvent. 
 
Figure 5-8: Nonylphenoxypoly(ethyleneoxy)ethanols abbreviated as (NP). The “n” 
represents the number of the ethylenoxy repeating units. 
 
 Surfactant solutions were prepared by dissolving 6.85 g of NP5 and 20.57 g of NP9 in 
123.23 mL of cyclohexane.  In a typical reverse micelle reaction two surfactant solutions are 
required.  The first solution is place into a 1000 mL three necked round bottom flask under 
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magnetic stirring.  The surfactant solution is degassed for about 20 minutes with nitrogen (N2) 
utilizing the schlenk line technique.  Aqueous metal solutions were prepared by dissolving 0.95 g 
of FeCl2.4H2O in 6.85 mL of water and 0.57 g of NiCl2.4H2O in 6.85 mL of water.  The other 
surfactant solution was stirred vigorously while slowly adding the Ni
2+
 solution.  Once the 
solution formed micelles and became clear, it was placed in an addition funnel above the round 
bottom flask and degassed in the same manner.   
Next the aqueous Fe
2+
 solution was added to the first surfactant solution and degassed for 
5 minutes.   The colorless surfactant solution presented in the reaction vessel turned pale green 
upon the addition of Fe
2+
 solution.  At this point the reverse micelles start to form around the 
aqueous Fe
2+
 solution.  Then 0.36 g of NaBH4 was added to the flask and allowed to react for 
20 minutes, at the end of which the micelle solution in the addition funnel containing the Ni
2+
 
was added to the reaction for 5 minutes.  The addition of second surfactant containing Ni
2+
 aids 
in the formation of the FeOx shell and passivation of the nanoparticles against further oxidation.  
The reaction was quenched by the addition of 100 mL of chloroform and 100 mL of methanol 
and subsequently washed with methanol to remove excess surfactant and cyclohexane, and then, 
the resultant particles were collected in methanol by magnetic separation.  After washing was 
complete the remaining methanol was decanted and the particles were dried in a vacuum 
desiccator.  As shown in the Figure 5-9, the as synthesized Fe@FeOx core shell nanoparticles 
were dispersed in 0.50 M sodium hydroxide (NaOH) solution and then treated with equivalent 
grams of sorbitol and were sonicated for 4 hours.  The Fe@FeOx nanoparticles were first coated 
with sorbitol to provide a negatively charged particle surface for the Ru(bpy) dye adhere to the 
particle surface.  The sorbitol treated nanoparticles were then magnetically separated and 50.00 
mg of Ru(bpy) dye in 2 mL of water was added.   The nanoparticle dye mixture was further 
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sonicated for 4 hours and freeze dried to obtain the nanoparticle dye mixture.  The next step is 
the encapsulation of this nanoparticle dye mixture by PLGA polymer.  The encapsulation was 
achieved by emulsification solvent evaporation technique as discussed in chapter 1. 
 
Figure 5-9: Schematic representation of the Fe@FeOx nanoparticle and Ru(bpy) dye 
mixture 
 
5.4.3. Overview of Emulsification solvent evaporation technique  
The encapsulation of the Fe@FeOx nanoparticles and Ru(bpy) dye by PLGA polymer 
was achieved by emulsification solvent evaporation technique.   Emulsification is a process of 
dispersing two immiscible liquids.   For emulsion solvent evaporation there are basically two 
systems to choose: oil-in-water (o/w) and water-in-oil (w/o).  The o/w systems are widely used 
compared to w/o systems due to the simplicity of the process and easy clean up requirements for 
obtaining the final polymeric particles.  In this process the active agents should be hydrophobic 
and a water immiscible solvent should be used.  In this research work the oil-in-water emulsion 
solvent evaporation technique was used to obtain PLGA composites containing Fe@FeOx 
nanoparticles and the Ru(bpy) dye. Dichloromethane (DCM) is the most commonly used water 
immiscible solvent for preparation of PLGA particles. 
The oil-in-water emulsification solvent evaporation technique consists of four major 
steps.  First step is the dissolution of the active agent in an organic solvent (dichloromethane) 
containing the polymer.  Second step is the emulsification of this organic phase, called dispersed 
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phase, in an aqueous phase called continuous phase followed by extraction of the solvent from 
the dispersed phase by the continuous phase, accompanied by solvent evaporation, transforming 
droplets of dispersed phase into solid particles.  The final step is the recovery and drying of 
composites to eliminate the residual solvent. 
5.4.4.  Preparation of PLGA composites containing Fe@FeOx nanoparticle and Ru(bpy) 
dye mixture 
Figure 5-10 shows the schematic representation of the o/w emulsion solvent evaporation 
technique used to prepare the PLGA composites.   The polymer solution was formed by 
dissolving 2 wt% of PLGA in dichloromethane (DCM).  The organic phase was formed by 
combining 50.00 mg of the nanoparticle-dye mixture and 3 mL of PLGA solution. This organic 
phase was sonicated for 5 minutes to achieve uniform dispersion.  This organic phase was then 
added to 50 mL of aqueous phase containing 3% w/v poly(vinyl alcohol) (PVA) as the stabilizer, 
to form the oil-in-water emulsion. PVA helps to reduce the surface tension of continuous phase, 
avoids the coalescence and agglomeration of the emulsion droplets formed and stabilizes the 
emulsion.  The emulsion was homogenized with Ultra Turrax IKA T-18 basic homogenizer at 
22,000 rpm for 5 minutes.  After that 100 mL distilled water was added to the oil-in-water 
emulsion, which dilutes the organic solvent concentration in water and leads to the hardening of 
the composites.  The solution was stirred overnight to evaporate the organic solvent (DCM) and 
then freeze dried.  The loading efficiency of the iron core nanoparticles and the thickness of the 
PLGA coating can be controlled by varying the ratios of PLGA, iron nanoparticles, and the 
fluorescent dye.  All characterization and evaluation studies described below were done utilizing 
the freeze dried PLGA composites. 
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Figure 5-10: Schematic representation of oil-in-water (o/w) emulsion solvent evaporation 
technique utilized for the encapsulation of the Fe@FeOx nanoparticles and Ru(bpy) dye 
into PLGA polymer 
 
The size distribution and the morphology of the prepared PLGA composites were 
determined using a scanning electron microscope (SEM) with a Zeiss EVO 50 (Carl Zeiss, Inc.).  
The core-shell morphology and size of the nanoparticles were determined by transmission 
electron microscope (TEM) with a Joel JEM-1230 (Joel Ltd.).   The loading efficiency of the 
iron nanoparticles and the dye, and the release rate of the dye were determined by fluorescence 
spectroscopy and thermogravimetric analysis (TGA) 
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5.5. Results and discussion 
The size and morphology of the as synthesized Fe@FeOx core shell nanoparticles was 
confirmed by transmission electron microscopy (TEM).  The TEM sample was prepared by re-
dispersing the Fe@FeOx nanoparticles in methanol, and then applied to a 300 mesh copper TEM 
grid with a carbon film.  Figure 5-11 shows the TEM image of the Fe@FeOx core shell 
nanoparticles.  A well-defined core shell nanostructures with a size distribution in the range of 10 
to 15 nm is observed.  The inner dark centers represent the metallic iron core and the outer light 
color rings represent the iron oxide shell.  These results confirm the core shell morphology of the 
synthesized Fe@FeOx nanoparticles. 
 
Figure 5-11: Transmission electron microscopy (TEM) image of Fe@FeOx core shell 
nanoparticles synthesized by reverse micelle technique. 
 
20nm 
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Scanning electron microscopy (SEM) was performed to determine the size distribution 
and the morphology of the prepared polymeric composites.  The freeze dried PLGA composites 
were re-suspended in water with sonication, mounted onto a carbon conductive tab (Ted Pella, 
Inc., Redding, CA, USA), and dried at room temperature overnight.  The sample was sputter 
coated with gold plasma prior to SEM imaging.   Figure 5-12 shows the SEM image of the 
magnetic PLGA composites, which are roughly around 200 nm–1.5 μm in size and show fairly 
spherical structure.  The size distribution of the composites is attributed to the oil-in-water 
droplet formation and the solvent evaporation from the polymer solvent interface.  In general, 
longer homogenization times and higher speed of the homogenizer produces higher shear 
induced by the homogenizer blade, thus, leading to smaller particle size.  Too much loading of 
the Ru(bpy) dye and the nanoparticles leads to the loss of morphological control and the 
composites turn into irregular shapes as seen in the Figure 5-12.  The most likely explanation to 
this would be that the Ru(bpy) dye could precipitate in due to lack of water during the Fe@FeOx 
nanoparticle-Ru(bpy) dye mixture formation.  The particle size of the precipitated dye could be 
bigger than the oil-in-water bubbles formed.  Thus disturbing the droplet formation and leading 
to smear formation.  The other speculation is that as the dye content is increased in the organic 
phase, more dye is likely to get solubilize into the aqueous phase as Ru(bpy) is a water soluble 
dye.  This leads to the disturbance in the formation of the droplet. 
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Figure 5-12: Scanning electron microscopy (SEM) image of the magnetic PLGA composites 
 
The loading efficiency of the prepared magnetic PLGA composites was determined using 
Thermogravimetric analysis (TGA) and fluorescence spectroscopy.  5 mg of the PLGA 
composite were dissolved in DCM; PLGA is soluble in DCM while the Fe@FeOx nanoparticles 
and the Ru(bpy) dye fall out in the organic solution.  To this DCM solution a known volume of 
water was added to extract the water soluble Ru(bpy) dye.  Fluorescence measurements were 
performed on the aqueous layer to determine the Ru(bpy) dye content in 5 mg of the composites. 
Fluorescence intensity of known concentration of Ru(bpy) dye was measured and a linear curve 
fit was performed which yields around 0.25% w/w fluorescent Ru(bpy) dye loading in the 
composites as shown in Figure 5-13.  Attempts were made to improve the loading efficiency of 
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the dye but it leads to the loss of the spherical morphology of the composites, as discussed 
earlier.   
 
Figure 5-13: Linear regression plot yielding a 0.25% w/w Ru(bpy) loading into the PLGA 
composites 
 
TGA results also confirmed 0.25% w/w Ru(bpy) dye loading and shows approximately 
50% w/w Fe@FeOx nanoparticles loading in the composite as shown in Figure 5-14.  The 
decomposition of PLGA polymer by itself occurs at around 200 ºC, but the PLGA composites 
start to degrade at around 160 ºC.  The PLGA polymer is in a form of amorphous bead but when 
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the PLGA composites are formed the polymer was dissolved in DCM and re-precipitated out.  
This causes an increase in the atacticity of the polymer.  Two decomposition events around 380 
ºC and 450 ºC are observed for Ru(bpy) corresponding to the decomposition of the bipyridyl 
rings.  The PLGA composites shows a small decomposition event around 400 ºC corresponding 
to Ru(bpy) dye indicating a trivial amount of the dye.  The Ru(bpy) dye loading obtained is very 
less and can be attributed to the loss of the water soluble Ru(bpy) dye during the emulsification 
process.  The Fe@FeOx nanoparticles do not undergo any decomposition till 600 ºC thus 
yielding a loading of around 50% in the composite. 
 
Figure 5-14: TGA plot showing the decomposition profile of PLGA composites containing 
Fe@FeOx nanoparticles and Ru(bpy) dye, PLGA and Ru(bpy) dye by itself 
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5.6. Ru(bpy) dye release studies 
Fluorescence spectroscopy was performed to study the release kinetics of the Ru(bpy) 
dye from the PLGA composites. Ru(bpy) dye is a fluorescent dye with excitation wavelength of 
470 nm and emission wavelength around 610 nm.  Therefore, the PLGA composites were 
excited at 470 nm using Cary Eclipse Fluorescence Spectrophotometer equipped with a xenon 
lamp.  As the dye is released from the composite, the fluorescence intensity decreases due to the 
quenching of the Ru(bpy) dye by the Fe@FeOx nanoparticles as discussed earlier, thus allowing 
for the determination of the release kinetics of the dye as a function of temperature.  The PLGA 
composites were dispersed in water and heated with 2.45 GHz microwave radiations by 
irradiating with a pulse of 1 second duration each utilizing a commercial microwave unit.  The 
microwave radiations heats up the magnetic nanoparticles by magnetic hyperthermia principle as 
discussed. 
 
Figure 5-15: Physical mechanism at each frequency range of electromagnetic spectrum 
range 
 
Electromagnetic (EM) radiation can be classified into ionizing radiation and non-ionizing 
radiation, based on whether it is capable of ionizing atoms and breaking chemical bonds as 
shown in the Figure 5-15. Non-ionizing EM radiations propagate within biological tissues with 
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reduced velocities, and are refracted, diffracted and reflected when encountering in-
homogeneities within tissues.   For heat generation the non-ionizing radiations of the EM 
spectrum are widely used by diversified system configurations.  Microwave radiations are widely 
used EM radiation to generate heat within the body. Microwaves are defined as the region of the 
non-ionizing spectrum from 300 MHz to 30 GHz.   Microwaves interact with biological systems 
by way of ionic conduction and rotation of polar molecules of water.  Microwave energy is 
generated by a magnetron, and transmitted either directly or by means of a waveguide.  The 
Federal Communications Commissions for industrial, scientific, and medical applications has 
allotted the 0.955 and 2.450 GHz frequency bands for hyperthermia applications.
182
    In the 
0.915 GHz band, resistive heating is achieved by collision of the freely moving ions within the 
body while at the 2.45 GHz frequency bands heat is generated but to the dielectric heating of 
water and fats within the body.  Due to this microwave energy leads to overheating of the fatty 
tissues.  Despite these problematic overheating, microwaves are still among the mainstream 
hyperthermia applications due to several appealing experimental and clinical results.  Also the 
overheating can be controlled by maintaining the exposure time of the microwave radiations as 
defined by the International Commission on Non-Ionizing Radiation Protection (ICNRP)
183,184
 
  
107 
 
 
Figure 5-16: Plot of fluorescence intensity vs time. The horizontal lines shows the 
fluorescent intensity at room temperature 22 °C, 30, 40, and 50 °C temperature as 
measured by fluorescence spectrometer. 
 
The magnetic nanoparticles when irradiated with the microwave radiations produce heat 
by magnetic hyperthermia principle as discussed earlier.  The 2.45 GHz frequency with 1 second 
pulse was used for the in-vitro experiments and past studies have shown that few seconds’ 
exposure to the microwave radiations does not have any major effect on the healthy tissue.
185,186
 
To achieve uniform heating of the composite sample and water as the reference, the turntable 
within the microwave unit was removed and the composite sample and water were heated from 
one to five times with a pulse of 1 second duration each.  The iron nanoparticles encapsulated 
within the composite absorb the microwaves and heats up providing local heating.  The PLGA 
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polymer swells up due to the heat produced leading to the release of the dye through the erosion 
of the polymer.  The bulk water temperature of the composite sample as well as the reference 
reached up to 32 °C after irradiating the sample five times with a pulse of 1 second duration 
each.  Fluorescent measurements were carried out after irradiating the sample for one to five 
times with 1 second pulse each, as well as heating the sample to 30, 40, and 50 °C.  The sample 
was just heated five times as further heating leads to drastic increase in the temperature of the 
sample.  Figure 5-16 shows the plot of the fluorescence intensity with time of irradiation of the 
sample by the microwaves and externally heating the sample at 30, 40, and 50 °C.  It can be seen 
that the rate of release of the dye at 2 seconds is equal to that of 30 °C and the 4 seconds 
irradiation release equals to 40 °C.  
5.7. Conclusion 
Successful encapsulate the drug analog Ru(bpy) dye and magnetic Fe@FeOx 
nanoparticles into the PLGA composites was achieved by oil-in-water emulsion solvent 
evaporation technique.   The local heating of the PLGA composites was also achieved by 
irradiating the Fe@FeOx nanoparticles with 2.45 GHz microwave radiations.  The release of the 
Ru(bpy) dye from the PLGA composites after microwave irradiation was successfully achieved.  
Also higher Ru(bpy) dye release from the composites by locally heating the sample with 2.45 
GHz microwave pulse compared to externally heating the composite sample was demonstrated. 
Fe
2+
and Fe
3+
 ions acts as a very good quencher for the fluorescent Ru(bpy) dye, which is 
observed with the decrease in the fluorescence intensity of the released dye at 610 nm when the 
temperature is increased externally or by irradiating the sample five times with 1 second pulse 
each from a 2.45 GHz commercial microwave unit.  The composite sample when irradiated with 
microwaves or externally heated at 30, 40 or 50 ˚C, the sorbitol layer on the nanoparticles 
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decomposes at that temperature.  The sorbitol was used to provide a barrier between the iron 
oxide nanoparticles and the Ru(bpy) dye so that they do not come in contact with each other 
leading to dynamic quenching of the Ru(bpy) dye.  The quenching of the Ru(bpy) dye by the 
iron oxide nanoparticles is observed when the composites are irradiated or heated externally.  As 
a result a systematic study of the quenching process of the ruthenium dye needs to be done.   To 
clearly understand the quenching process of the Ru(bpy) dye in-situ measurements of the dye 
release need to be done.  For this reasons Radio frequency (Rf) radiations were used instead of 
2.45 GHz microwave radiations to generate heat from the magnetic iron nanoparticles by 
magnetic hyperthermia principles.  It is easier to mount an Rf frequency coil on the sample 
carrying out simultaneous heating and fluorescent measurements.  Also a bench top fluorescence 
spectrometer equipped with 530 nm laser source was used to carry out in-situ measurements.  An 
Rf frequency coil was mounted on the sample and then fluorescence measurements are carried 
out.    A detailed explanation of the experimental set up and the results obtained will be given in 
chapter 6. 
        
   
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. Ferrofluid based drug delivery system with dual modal imaging 
and therapeutic applications 
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6.1. Overview 
As discussed earlier a drug delivery system made up of biodegradable and biocompatible 
PLGA polymeric composites containing the Fe@FeOx nanoparticles and the drug analog has 
been successfully designed.  But as seen in the previous results the PLGA composites 
synthesized were poly-dispersed with a wide size distribution of around 200 nm–1.5 μm.  For in-
vitro applications mono-dispersed PLGA composites with higher dye loading efficiency are 
desirable.  To obtain mono-dispersed PLGA composites, the magnetic Fe@FeOx nanoparticles 
need to be dispersed in either organic or aqueous medium.   The PLGA composites earlier 
synthesized in chapter 5 were prepared by oil-in-water (o/w) emulsion technique.  The basic 
principle of this technique is that both polymer and the active agents to be encapsulated need to 
be dispersed/ dissolved into the organic phase (DCM), and the resultant organic phase is 
emulsified into the water phase containing the emulsifier of choice.  In the earlier case when 
Fe@FeOx nanoparticle-Ru(bpy) dye mixture was encapsulated into the PLGA polymer, the 
nanoparticle-dye mixture did not form a stable disperse into DCM.  So it was a solid-in-oil-in-
water (s/o/w) emulsion, in which a solid is dispersed into the organic phase which is then 
emulsified in the aqueous phase.
187
  But the s/o/w technique has certain drawbacks such as 
formation of poly-dispersed composites and increase in the burst release of the active agent.  In 
s/o/w technique very low and uniform particle size of the active agent is required for the 
complete encapsulation.
188
    Therefore the poly-dispersed in the PLGA composites could have 
come from the poly-dispersed Fe@FeOx nanoparticle-Ru(bpy) dye mixture.  To overcome this 
problem the nanoparticle-dye mixture needs to be dispersed into the organic phase.  The Ru(bpy) 
dye is soluble in the aqueous as well as organic phase but the Fe@FeOx nanoparticles do not 
disperse into organic as well as the aqueous phase.  So, it is essential to obtain a stable dispersion 
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of the magnetic nanoparticles into the desired solvent.  This can be achieved by using a ferrofluid 
instead of the iron nanoparticles.  
This chapter first describes the synthesis of the chloroform based ferrofluid by 
thermolysis technique followed by its characterization.  The next step is the preparation of the 
PLGA composites utilizing the synthesized ferrofluid and the drug analog by oil-in-water 
emulsion solvent evaporation technique.  The PLGA composites were further functionalized with 
folic acid for targeted delivery.  The functionalization of the PLGA was achieved utilizing 
carbodiimide chemistry and will be discussed in detail in section 6.4.  The release of the drug 
analog from the functionalized PLGA composites was studied by fluorescence spectroscopy 
while placing the sample in a radio frequency (Rf) induction coil.  The PLGA composites were 
also investigated by magnetic resonance relaxivity measurements for its application in MRI 
6.2. Ferrofluid 
Ferrofluids are stable colloidal suspensions of nanoscale magnetic particles into a carrier 
fluid, usually organic solvent or water.
148,189
  The magnetic nanoparticles have an average 
particle size of about 10 nm that are suspended by Brownian motion and do not settle out, even 
when exposed to a strong magnetic, or gravitational field.  The magnetic nanoparticles are 
mainly nanoscale magnetite or maghemite. In the absence of a magnetic field, the magnetic 
moments of the nanoparticles are randomly distributed and the ferrofluid has no net 
magnetization.  But when a magnetic field is applied to a ferrofluid, the magnetic moments of the 
nanoparticles orient along the field lines almost instantly. The magnetization of the ferrofluid 
responds immediately to the changes in the applied magnetic field and when the applied field is 
removed, the moments randomize quickly. 
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 The magnetic nanoparticles of the ferrofluid are coated with a stabilizing dispersing 
agent that prevents the particle agglomeration even when a strong magnetic field is applied to the 
ferrofluid.  These stabilizers prevent the nanoparticles from clumping together, ensuring that the 
particles do not form aggregates that become too heavy to be held in suspension by Brownian 
motion.  There are two main types of stabilizers used for dispersing magnetic nanoparticles such 
as the surfactant stabilized nanoparticles and ionically stabilized nanoparticles.  
Tetramethylammonium hydroxide is the most commonly used ionic stabilizer for polar solvents 
based ferrofluid.  The positively charged tetramethylammonium hydroxide [N(CH3)4
+
] cation 
forms a diffuse shell around the negatively charged nanoparticle surface, inducing electrostatic 
repulsion between the neighboring particles.  For non-polar solvents based ferrofluid, surfactants 
are used to coat the nanoparticle surface that induces steric repulsion on the neighboring 
nanoparticles.  The most commonly used surfactants are oleic acid, citric acid, and soy lecithin.  
A surfactant has a polar head which adsorbs to a nanoparticle and non-polar tail that sticks out 
into the carrier medium preventing the agglomeration of the nanoparticles.  The stability of the 
ferrofluid is influenced by several parameters such as an optimum size range of the 
nanoparticles, viscosity of the carrier liquid, length of the surfactant, temperature, and magnetic 
field strength.  Various techniques have been shown to produce magnetic nanoparticles such as 
wet grinding, co-precipitation, micro-emulsion, and thermal decomposition of metal salts 
(thermolysis).
189-191
  After the synthesis of the nanoparticles, additional steps are typically 
required to coat them with the appropriate stabilizer. 
6.2.1. Synthesis 
Thermolysis is a synthetic technique where in the nanoparticles are synthesized by 
thermally decomposing the metal precursor in high boiling organic solvents containing 
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stabilizing surfactant.
192,193
  Mono-dispersed nanoparticles can be achieved through thermolysis 
technique.  Furthermore, utilizing this technique the surfactant coating of the nanoparticle can be 
achieved in a single step process. 
 
Figure 6-1: Synthetic scheme for the design of the chloroform based ferrofluid 
 
 
Figure 6-2: Schematic representation of the magnetic nanoparticles coated with sodium 
oleate in the ferrofluid.  The sodium oleate chains induces steric repulsion on the 
neighboring particles preventing the agglomeration 
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Chloroform based ferrofluid was synthesized by thermolysis technique under ambient 
conditions.  1.00 g of iron (II) chloride tetrahydrate (FeCl2.4H2O) and 2.50 g of sodium oleate 
are placed in a 100 mL one neck round bottom flask.  Sodium oleate is used here as a surfactant 
to coat the magnetic nanoparticles as shown in Figure 6-2.  The sodium oleate induces steric 
repulsion between the neighboring nanoparticles thus preventing agglomeration.   Then 25 mL of 
n-butanol is slowly added to the flask under magnetic stirring.  The reaction solution is quickly 
heated to reflux conditions for an hour.  During which the reaction solution undergoes a color 
change from dark orange to grey and finally to jet black at the end of 1 hour reflux.   After an 
hour the reaction solution was allowed to cool to room temperature and quenched with the 
addition of 100 mL methanol.  Throughout the reaction the particles did not seem to stick to the 
magnetic stirrer during the reaction.  The nanoparticles are magnetically extracted and further 
washed several times with methanol.  The methanol washing step is necessary to remove any 
excess of the sodium oleate surfactant.  To prepare the chloroform based ferrofluid, the 
nanoparticles were taken in a vial and chloroform was slowly added under sonication.  The 
colloidal stability of the prepared ferrofluid was checked with a rare earth magnet.  The resulting 
ferrofluid is stable for over six months without visual degradation.   
The next step is the preparation of the PLGA composites utilizing the ferrofluid and the 
drug analog.  In previous work Ru(bpy) dye was used as the drug analog, but the loading 
efficiency was too low  around 0.25%.  Another dye Rose Bengal was used but it also suffered 
from the same problem of poor loading.  Both Ru(bpy) and Rose bengal are water soluble and 
leached out during the emulsification process leading to poor encapsulation efficiency.  
Moreover most of the anticancer drugs are water insoluble so we need a water insoluble drug 
analog. Rhodamine B base is a sparingly soluble in water.    Rhodamine B base is a fluorescent 
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dye belonging to the family of fluorone dyes and its structure is as shown in Figure 6-3.  
Rhodamine B base has and excitation wavelength around 540 ± 2 nm and emission wavelength 
around 580 ±2 nm.  Rhodamine B base also undergoes dynamic quenching by Fe
2+
and Fe
3+
 ions 
through excited state charge transfer mechanism. 
176,194
 
 
Figure 6-3: Chemical structure of Rhodamine B base dye 
 
6.3. Preparation of the PLGA composites containing the Ferrofluid and Rhodamine 
B dye 
The PLGA composites containing the ferrofluid and Rhodamine B base dye were 
synthesized by oil-in-water emulsion solvent evaporation technique as discussed earlier with a 
slight modification.  In the previous work the first step was the preparation of the nanoparticle-
dye mixture. But it is know that the metal ions quench the dye through excited state charge 
transfer mechanism. The efficiency of the quenching depends on the distance between the donor 
and the acceptor species.
177
  So, if the distance between the donor and acceptor species is 
increased the quenching process can be restricted.   
117 
 
 
Figure 6-4: Schematic representation of modified oil-in-water (o/w) emulsion solvent 
evaporation technique utilized for the encapsulation of the ferrofluid and Rhodamine B 
base dye into PLGA polymer 
 
Figure 6-4 represents the schematic representation of the synthetic scheme for preparing 
the PLGA composites.  Firstly the polymer solution was formed by dissolving 200.00 mg of 
PLGA in 3 mL of dichloromethane (DCM).  This polymer solution was divided into half.  To the 
first half 1 mL of chloroform based ferrofluid was added while 20.00 mg of the Rhodamine B 
dye was added to the other half polymer solution.  Both the ferrofluid and the dye containing 
solutions were sonicated for 5 minutes to achieve uniform mixing.  The two polymer solutions 
were then mixed together to form the organic phase.  This organic phase was then added to 50 
mL of aqueous phase containing 2% w/v poly(vinyl alcohol) (PVA) as the stabilizer, to form the 
oil-in-water emulsion. PVA helps to reduce the surface tension of continuous phase (aqueous 
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phase), avoids the coalescence and agglomeration of the emulsion droplets formed and stabilizes 
the emulsion.  The emulsion was homogenized with Ultra Turrax IKA T-18 basic homogenizer 
at 60,000 rpm for 1 minute.  After that 50 mL of 0.25% w/v PVA solution was added to the oil-
in-water emulsion and further homogenized at 40,000 rpm for another minute.  This dilutes the 
organic solvent concentration in water and leads to the hardening of the composites.  The 
solution was stirred for 4 hours to evaporate the organic solvent and then freeze dried.  PLGA 
composites containing just the dye as well as the ferrofluid were also synthesized by the same 
procedure as controls.  The prepared PLGA composites were stored in vial till further use. 
6.4. Functionalization of the PLGA composites with Folic acid 
For an effective drug delivery active targeting of the active agent to the tumor site is 
necessary.  As discussed in chapter 1, Folic acid (FA) is a water soluble vitamin that can be used 
for tumor targeting via folate receptor mediated endocytosis.    Folate receptor has been known 
to be greatly over expressed in several human tumors such as ovary, lung, breast, kidney, and 
brain. Folic acid has emerged as an attractive ligand for drug targeting due to its low molecular 
weight (MW-441), which allows for good tissue penetration.  Also FA can be easily attached to 
the PLGA composites through carbodiimide chemistry.  The PLGA composites can be 
functionalized with FA prior to the composite formation or can be conjugate to the pre formed 
PLGA composites.  The FA conjugation prior to the composite formation is preferred as it is 
found to be robust as compared to the functionalization of the pre formed composite. 
The functionalization of PLGA by FA was carried out in three steps.  The first step was 
modification of the PLGA surface by controlled aminolysis to produce primary and secondary 
amine groups on the surface.  The second step was activation of the FA by EDC and NHS.  And 
the final step was the conjugation of the activated FA with aminolyzed PLGA. 
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6.4.1. Controlled aminolysis of PLGA 
 
Figure 6-5: Controlled aminolysis of the PLGA polymer with ethylenediamine 
 
Aminolysis is a technique that is used for surface modification of polyesters.
195-197
 The 
reaction proceeds via nucleophilic attack on the carbonyl carbon to form a positively charged 
tetrahedral intermediate.  Under basic conditions, the tetrahedral intermediate is deprotonated 
and the reaction proceeds to the formation of an amide and an alcohol as shown in Figure 6-5.   
200.00 mg of premade PLGA were immersed in aqueous solution of 5 mL of 0.05 M 
ethylenediamine (ED) for 15 minutes.  The aminolyzed PLGA was then washed three times with 
120 
 
ice cold water to remove any excess of ethylenediamine.  IR spectroscopy was performed on the 
aminolyzed PLGA to confirm the presence of the amino groups. 
6.4.2. Activation of Folic acid (FA) 
The chemical conjugation of aminolyzed PLGA with folic acid (FA) was carried out 
utilizing the carbodiimide chemistry.  Carbodiimide is a functional group containing the general 
formula RN=C=NR.  In synthetic chemistry carbodiimides are used to form amide linkage 
between carboxylic acids and amines.  Dicyclohexylcarbodiimide (DCC) is a zero length 
crosslinking agent used to couple carboxyl groups to primary amines.  DCC reacts with a 
carboxyl group forming an amine-reactive O-acylisourea intermediate.  This intermediate may 
react with an amine, yielding an amide.  However, the failure to react quickly with an amine 
results in hydrolysis and regeneration of the carboxyl moiety.   The addition of N-
hydroxysuccinimide (NHS) stabilizes the amine-reactive intermediate by converting it to an 
amine-reactive NHS ester, thus increasing the efficiency of DCC-mediated coupling reactions.  
The amine-reactive NHS ester intermediate has sufficient stability to permit two-step 
crosslinking procedures. 
The carboxylic group of folic acid was activated by DCC and NHS as shown in the 
synthetic scheming in Figure 6-6.  Briefly, 1.00 g of FA was dissolved in 20 mL of 
dimethylsulfoxide (DMSO) in a 100 mL one neck round bottom flask under magnetic stirring.  
Then 1.10 g of NHS and 1.10 g of DCC were added to the FA solution (folic acid/NHS/DCC 
molar ratio=1:1.1:1.1).  The reaction mixture was allowed to react at room temperature for 12 
hours in dark.  At the end of 12 hours of reaction, white byproduct N,N'-dicyclohexylurea 
precipitates are found.  The reaction mixture is filtered through glass wool plug and precipitated 
with ethyl ether.  The precipitated FA-NHS ester was pelleted by centrifugation and the 
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supernatant was removed.  The precipitated FA-NHS ester was vacuum-dried and stored in an 
amber vial till further use. 
 
Figure 6-6: Activation of the carboxyl group of FA with DCC and NHS to form the FA-
NHS ester 
6.4.3. Conjugation of FA-NHS ester with aminolyzed PLGA 
200.00 mg of aminolyzed PLGA was dissolved in 10 mL DCM in a 25 mL round bottom 
flask under magnetic stirring.  Then 200.00 mg of FA-NHS ester was added to it and was let to 
react for 4 hours.  After the end of 4 hours the FA functionalized PLGA (FA-PLGA) was 
precipitated with ethyl ether.  The precipitated FA-PLGA was pelleted by centrifugation and the 
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supernatant removed. The pellet was re-dissolved in DCM (<1 mL), precipitated, and centrifuged 
once more to remove any unreacted FA-NHS ester.  
This FA -PLGA polymer was used to synthesis the composites utilizing the ferrofluid and 
Rhodamine B dye by modified oil-in-water emulsion solvent evaporation technique as discussed 
in section 6.3. 
6.5. Results and Discussion 
The ferrofluid and PLGA composites were characterized by x-ray diffraction, electron 
microscopy, vibrating sample magnetometry, and fluorescence spectroscopy to determine the 
phase, size and morphology, saturation magnetization and the loading percentages of the dye and 
nanoparticles.   The chloroform based ferrofluid was evaporated in a watch glass to obtain dried 
nanoparticles powder.  These dried nanoparticles were used for the powder XRD and VSM 
measurements. 
Powder x-ray diffraction (XRD) measurements were performed using a Panalytical 
X’pert pro diffractometer at a scanning step of 0.05º with a 2θ range from 20º to 80º using a 
graphite monochromated Cu-Kα radiation source. Sample was ground and pressed onto a no 
background, low volume silicon holder.  Figure 6-7 shows the powder XRD pattern of the as 
synthesized ferrofluid nanoparticles with an overlay of the data obtained from the JSPDS 
reference powder diffraction pattern of magnetite.
198
  The pattern shows a pure phase magnetite 
(Fe3O4).  Major diffraction peaks for magnetite at 30.125°, 35.483°, 37.117°, 43.124°, 53.501°, 
57.033°, 62.949°, 71.430°, 74.493°, 75.504°, and 79.504° correspond to the (220), (311), (222), 
(400), (422), (511), (440), (620), (533), (622), and (444) miller indices, respectively.  The peaks 
were indexed by the JCPDS database for magnetite (fd3m, card#01-086-1343). 
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Figure 6-7: Powder x-ray diffraction pattern of as synthesized ferrofluid 
 
The size and morphology of the synthesized ferrofluid was confirmed by transmission 
electron microscopy (TEM).  Figure 6-8 shows relatively uniformed size spherical nanoparticles 
with average diameter of 10±5 nm.  The spherical nanoparticles seem to be agglomerated and not 
mono-dispersed in the TEM image.  The agglomeration can rise from the TEM sample 
preparation.  For the TEM grid preparation the dried magnetite nanoparticles were dispersed in 
methanol and then around 5 μL of the dispersed solution was placed on the copper grid.  We 
believe that the agglomeration of the particles is induced by drying of the ferrofluid 
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Figure 6-8: TEM image of the magnetite nanoparticles in the ferrofluid. 
 
The FA functionalization of the PLGA composites was confirmed by both FTIR and UV-
Vis. spectroscopy.  The appearance of the amide linkage in the FTIR confirms the covalent 
attachment of the FA to PLGA.  The presence of the characteristic bands of FA in the FA 
conjugated PLGA also confirms the covalent attachment of FA. 
Figure 6-9 shows the IR spectra of PLGA, aminolyzed PLGA, FA functionalized PLGA 
and FA by itself.  From the spectrum of PLGA, it can be observed that there is a strong 
characteristic band at 1740 cm
-1
 corresponding to the  stretching vibrations of the carbonyl group 
(C=O), the bands at 2940 and 2990 cm
-1
 are assigned to the C–H stretching vibrations of the –
CH2 groups in the backbone chains of PLGA.  Similarly, the bands at 1160 and 1070 cm
-1
 are 
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attributed to C–O stretching of the ester group.  When aminolyzed PLGA was analyzed by IR, 
similar peaks to those of PLGA were observed with additional bands appearing at 1640 and 1570 
cm
-1
 due to N-H bending vibrations of amine group (NH2).  The presence of this band confirms 
the presence of amine groups on the PLGA.   The folic acid functionalized PLGA (FA_PLGA) 
shows characteristic bands of PLGA as well as folic acid. The band at 3550 and 3300 cm
-1 
corresponding to O-H and N-H stretching vibrations of amide group, 1610 cm
-1
 corresponds to 
the C=O stretching vibrations of amide group  and 1380 cm
-1
 corresponding to C-N stretch for 
amide group.  The appearance of the characteristic bands of amide group confirms the covalent 
attachment of folic acid with PLGA  While the IR spectrum of folic acid is characterized by 
bands between 3600 and 3000 cm
-1
 are due to the OH stretching and N-H stretching vibration 
bands, band at 1670 cm
-1
 for C=O stretching vibrations from carboxyl group (COOH) and 1600 
cm 
-1
 for N-H bending vibrations of amine group (NH2).
177
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Figure 6-9: IR spectra of PLGA, aminolyzed PLGA (PLGA-NH2), FA functionalized 
PLGA and FA 
 
Further the FA functionalization of PLGA was confirmed by UV-vis spectroscopy.  
Figure 6-10  shows the absorbance spectra of the FA functionalized PLGA polymer (FA-PLGA) 
and folic acid by itself.  The FA absorbs UV light and has absorption peaks at 210, 280 and 360 
nm.
199,200
  The absorbance spectra of the FA functionalized PLGA also shows absorbance 
maxima at 280 and 360 nm confirming the covalent attachment of the folate.  The FA and FA-
PLGA samples for absorbance measurements were prepared by dispersing about 1 mg each in 
water.  The absorbance of the aqueous suspension was measured in a quartz cuvette.   
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Figure 6-10: UV-Vis absorbance spectra of the FA functionalized PLGA polymer.  Inset 
shows the absorbance spectra of pure folic acid (FA) 
 
Scanning electron microscopy was performed on Hitachi SU-70 field emission scanning 
electron microscope to evaluate the size distribution and morphology of the magnetic PLGA 
composites and the FA-PLGA composites containing the dye and the ferrofluid.  Both PLGA 
and FA-PLGA composites samples were prepared by lightly sprinkling the composite powder on 
a conductive carbon tape mounted on the sample holder.   The sample was then sputtered with 
gold to make it conductive and reduce charging.  As seen in Figure 6-11 the PLGA composites 
are relatively uniform sized with an average diameter of 300±50 nm while the FA-PLGA 
composites are found to be spherical with a wider size distribution.  The FA-PLGA composite 
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looks as if they are interconnected and we speculate that it occurs due to excessive charging of 
the FA-PLGA composites even after sputtering it with conductive gold.    
 
Figure 6-11: SEM image of the PLGA composites utilizing the ferrofluid and Rhodamine B 
dye. (A) PLGA composites, (B) FA-PLGA composites 
 
The loading efficiency of the prepared PLGA composites was determined by 
fluorescence spectroscopy.  Rhodamine is acetone soluble so 4.00 mg of the PLGA composite 
were dissolved in 10 mL of acetone and filtered to remove the iron oxide nanoparticles. 
Fluorescence measurements were performed on the filtrate to determine the dye content in 4 mg 
of the composites.  Fluorescence intensity of known concentrations of dye was measured and a 
linear curve fit was performed which yields around 1.97% w/w dye loading in the PLGA 
composites containing both dye and ferrofluid. 
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Figure 6-12: Linear regression plot yielding a 1.97 % w/w Rhodamine B dye loading into 
the PLGA composites 
 
Thermogravimetric analysis (TGA) was performed on the PLGA composites containing 
the dye and ferrofluid (magnetic PLGA comp.), as well as the controls- PLGA dye composite, 
PLGA ferrofluid composite and PLGA by itself.  As can be seen in Figure 6-13 TGA plot yields 
around 2 % w/w Rhodamine B dye and 6.67 % w/w magnetite nanoparticle loading.  The 
decomposition event around 240º C attributed to the decomposition of PLGA as seen in figure.   
The decomposition event around 240º C is observed in the magnetic PLGA composites 
decomposition profile.   The Rhodamine B dye yields two decomposition events around 315 º C 
and 430 º C. A trivial decomposition event is observed at 315º C and 430º C attributed to the 
decomposition of Rhodamine B dye in the magnetic PLGA composites decomposition profile.   
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The ferrofluid shows a decomposition event around 200º C due to the decomposition of the 
sodium oleate surfactant on the surface of the particles.  The magnetite nanoparticles thereafter 
are stable and show no degradation till 600º C.  
 
Figure 6-13: TGA plot showing the decomposition profile of the PLGA composites and the 
controls 
 
Magnetic characterization was performed on the chloroform based ferrofluid as well as 
the PLGA composites by room temperature vibrating sample magnetometer (VSM) after drying 
the fluid.  Figure 6-14 shows a hysteresis plot of the as synthesized ferrofluid and PLGA 
composites.  The saturation magnetization of the iron oxide nanoparticles was around 105 emu/g.  
As seen in the inset the corecivity of magnetite nanoparticles is found to be negligible.  The 
saturation magnetization of the bulk magnetite is found to be around 90-120 emu/g.  The 
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decrease in the magnetization of the magnetite nanoparticles is attributed to the surfactant 
coating on the surface of the particles.  The inset shows the hysteresis plot of the PLGA 
composites containing the dye and the ferrofluid yields net magnetization around 8.18 emu/g.  
Utilizing the TGA data for weight correction the net magnetization of PLGA composites was 
found to be 100.00 emu/g.  The hysterysis loop for the PLGA composites is observed to be very 
noisy because the volume of magnetite nanoparticles is very less within the PLGA composites as 
well as the particles is randomly spread within the composites. 
 
Figure 6-14: Room temperature VSM data of the as-prepared ferrofluid material plotted as 
magnetization (emu/g) versus applied field (Oe) 
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Fluorescence spectroscopy was employed to study the release kinetics of the Rhodamine 
B dye from the PLGA composite while placing the sample in a radio frequency (Rf) induction 
heating coil.  Fluorescence measurements were performed on an open bench top HORIBA Jobin 
Yvon spectrometer equipped with a 535 nm laser source and synapse CCD detector shown in the 
Figure 6-15.   
 
Figure 6-15: Block diagram of the open bench top fluorescence spectrometer equipped with 
laser and the Rf heating coil set 
 
6.5.1.Rf induction heating 
Rf induction heating was carried out using Ambrell Inc. Model Easyheat 0224 induction 
heating system.  In a basic induction heating setup shown in Figure 6-16, a solid state Rf power 
supply sends an AC current through an inductor coil (often a copper coil).  The passage of 
current through this coil generates a very intense and rapidly changing magnetic field in the 
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space within the inductor coil and the sample to be heated is placed inside the coil.  The intense 
alternating magnetic field inside the inductor coil repeatedly magnetizes and de-magnetizes the 
iron oxide nanoparticles. This rapid flipping of the magnetic domains causes considerable 
friction and heating inside the material. The magnetic hyperthermia induced by Rf radiations is 
termed as Rf hyperthermia.   
 
Figure 6-16: Block diagram of the basic induction heating coil system 
 
The Rf hyperthermia technique offers benefits over existing hyperthermia treatments 
such as the technique can be localized using suitable Rf coils.
201,202
  Also Rf can be used for 
heating deep-seated tumors compared to microwave hyperthermia that has a poor depth of 
penetration, which makes it unsuitable for treatment of deep-seated tumors.  The microwave 
radiations also heats up the surrounding water molecules by dielectric heating producing 
excessive heat.
186
  Another major benefit of Rf hyperthermia is that it can be integrated into 
magnetic resonance imaging (MRI) systems for simultaneous treatment and monitoring.
202
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Figure 6-17: Plot of fluorescence intensity with the time of Rf induction heating of the 
PLGA composites. An increase in the fluorescence intensity is observed with time. 
 
The PLGA composites were dispersed in water and sonicated for about 15 minutes to 
remove the aggregated particles and then magnetically extracted and re-dispersed in water.  In-
situ fluorescence measurements were carried out on the dispersed PLGA composites at every 30 
seconds time interval for 30 minutes while the sample was placed in the Rf induction coil.  
Figure 6-17 shows that the fluorescence intensity of the PLGA composites increases linearly 
with time of Rf induction heating.   
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Figure 6-18: Plot of fluorescence intensity with the time of pulsed Rf induction heating of 
the PLGA composites. An increase in the fluorescence intensity is observed when the Rf 
pulse is switched ON and the intensity decreased when the Rf pulse is switched OFF 
 
A pulsed Rf treatment of the PLGA composites was also carried out which showed a 
corresponding increase in the rate of the dye release when the PLGA composites were heated (Rf 
pulse ON) and the rate of dye release decreases when RF pulse was OFF.  As seen in Figure 6-18 
the fluorescent intensity increases slightly in the first 10 minutes when the RF pulse is OFF, due 
to the burst release of the dye at the surface of the composites.  For the next 10 minutes i.e. 
between 10 to 20 minutes when the Rf pulse is ON an increase in fluorescent intensity is 
observed.  An insignificant increase in intensity is observed from 20 to 30 minutes when the Rf 
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pulse OFF and that is due to the remnant heat left when the Rf pulse was ON.  With the next Rf 
pulse ON between 30 to 40 minutes, a significant increase in the intensity is observed and again 
the intensity decreases when the Rf pulse is switched OFF between 40-50 minutes. 
 
Figure 6-19: Plot of DLS results showing the increase in size with the increase in 
temperature 
 
We speculate that when the magnetite nanoparticles are inductively heated that heat up 
the surrounding polymeric composite leading it to swell.  The swollen polymeric composites in 
turn lead to the release of Rhodamine B dye.   The swelling up of the PLGA composites due to 
the heat is confirmed by dynamic light scattering measurements.  Figure 6-19 shows the plot of 
temperature vs. the average particle size of the PLGA composites containing the dye and 
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ferrofluid as well as the PLGA composites by itself.  An increase in the size of the composites is 
observed with increase in the temperature.  Similar results were obtained for PLGA controls. 
6.6. MRI contrast application 
This ferrofluid was also investigated in vitro by magnetic resonance relaxivity 
measurements for its application in magnetic resonance imaging.  The magnetic resonance 
imaging (MRI)/spectroscopic experiments were performed on a 2.4 T/40 cm bore MR system 
(Biospec/Bruker).  For magnetic resonance relaxivity measurements the PLGA composites were 
dispersed in low melting agarose gels to avoid settling of the composites. 
6.6.1. MRI sample preparation 
The 1% agarose (w/v) gels were prepared by dissolving agarose powder in deionized 
water. The solution was heated in a microwave oven while stirring occasionally to ensure 
complete dissolution of agarose.  The MRI relaxation times were measured for gels containing 
PLGA composites with concentrations of 0.6700, 0.3350, 0.1675, 0.0838, and 0.0419 mM.   A 
control sample without PLGA composites was measured.   
The MRI/spectroscopic experiments were performed by a collaborator and the 
experimental details followed were as follows.  Spectroscopic T1 and T2 
1
H relaxation 
measurements of the PLGA composites dispersed in agarose gel were conducted using an 
inversion recovery sequence with eight inversion times (TI) and repetition times (TR) at least 
five times the expected T1 value.  For the T2 measurements, a multi-spin-echo CPMG sequence 
was employed with several echo times (TE) and TR values at least five times the expected T1. 
The relaxation times were computed from least-squares fitting of the exponentially varying 
signals using analysis routines available at the MR system. Relaxivities were extracted from 
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graphs of relaxation rates (1/T1 and 1/T2) versus concentration.  The concentration range used for 
the relaxivity measurements was in the range 0.0419-0.6700 mM.   
6.6.2.MRI results  
 
Figure 6-20: Relaxivity plot for first MRI measurements 
 
In Figure 6-20, the relaxation rates R1=1/T1 and R2=1/T2 are shown as a function of 
concentration of the PLGA composites. The relaxivities R1 and R2, representing the slopes of 
these curves, are 0.1 s
-1
mM
-1
 and 58.7 s
-1
mM
-1
 respectively.  Iron oxide nanoparticles are known 
to be T2 enhancement agent as they have high magnetic susceptibilities and generate high 
magnetic field gradients near their surfaces. These gradients create local magnetic field 
inhomogeneities that cause rapid dephasing of nearby proton spins, thus increasing proton 
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transverse relaxivities (R2) which is evident from the relaxivity plot.  A negligible reduction in 
the transverse relaxivity (R2) is observed due to the polymeric coating on the nanoparticles. 
   
 
Figure 6-21: MRI T2-weighted image of the PLGA composites sample in agarose with 
varying concentration of the magnetite (iron oxide) nanoparticles. 
  
As discussed earlier the iron oxide (magnetite) nanoparticles are effective in reducing the 
T2 relaxation time, thereby inducing a signal darkening on the T2-weighted MRI images.  As 
seen in Figure 6-21 as the concentration of the iron oxide nanoparticles increases the image 
contrast the respective micro-centrifuge tubes increases.  This phenomenon is caused by the 
significant enhancement of transverse proton relaxation in the vicinity of areas containing 
magnetic iron oxide, thus leading to quick fading of MR signals.   
6.7. Conclusion 
In conclusion, the chloroform based ferrofluid containing monodisperse magnetite 
nanoparticles were produced using thermolysis technique.  The magnetite nanoparticles of the 
ferrofluid were mono-dispersed with an average diameter of 10± 5 nm and were highly magnetic 
with a saturation magnetization of 105 emu/g. The ferrofluid was found to be stable over six 
months.  The PLGA composites were synthesized using the ferrofluid and Rhodamine B dye by 
modified oil-in-water emulsion evaporation technique.   The PLGA composites were further 
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functionalized with folic acid to achieve targeted delivery.   The release of the dye from the 
PLGA composite when place in a Rf induction coil was determined by fluorescence 
spectroscopy and an increase in the fluorescent intensity was observed with increase in the Rf 
induction heating time.   A pulsed Rf treatment of the PLGA composites was also carried out 
which shows a corresponding increase in the rate of dye release when the composites are heated 
(RF pulse ON) and rate decrease (RF pulse OFF). The dye is released from the PLGA 
composites due to the swelling of the polymer and this is confirmed by dynamic light scattering 
measurements.  Magnetic resonance imaging was also performed using the PLGA composites 
which showed enhancement in the T2-weighted image contrast and thus negligible reduction in 
the contrast capabilities of the iron oxide particles (R2 = 58.7 s
-1
mM
-1
).  The PLGA composites 
containing the dye and the iron oxide nanoparticles thus show a potential for being a dual modal 
imaging and therapeutic delivery system with reduced drug related toxicity and better drug 
activity. 
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Chapter 7. Conclusions 
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The goal of this dissertation was to design a dual modal controlled release drug delivery 
system with cellular targeting capabilities.  As discussed in this dissertation the design of the 
drug delivery carrier consisted of magnetic nanoparticles as a core with a biocompatible polymer 
coating.  The incorporating of magnetic iron/iron oxide nanoparticles into the polymeric 
composites was to achieve local heating of the composites through magnetic hyperthermia 
principles. These polymeric composites are expected to be superior to conventional routes of 
drug administration because the use of nanocomposites would improve the lifetime of the drug in 
the circulation, increase the accumulation of the drug at the tumor site through specific site 
reorganization mechanism, increase the time that the tumor would be exposed to the drug, and 
minimize the amount of drug able to enter healthy tissue as a result of the entrapment of the drug 
within a polymeric matrix.  A summary of some of the main conclusions in this dissertation work 
is presented as below: 
1. The first step in the design of the drug delivery was to achieve a complete polymeric 
coating on the magnetic iron oxide nanoparticles.  Magnetic iron oxide nanoparticles 
were synthesized by one-pot polyol technique.  This process enabled the liquid polyol to 
act not only as a solvent, but also as a mild reducing agent and a surfactant for the 
stabilization of the nanoparticles.  The iron oxide nanoparticles synthesized were then 
coated with a copolymer of styrene- poly (styrene-co-vinylbenzylchloride-co-
divinylbenzene) (PSVBDVB) which has better mechanical properties compared to 
polystyrene. Also, monomer vinylbenzylchloride used has chlorine on its para position 
that doesn’t interfere in the polymerization process and provides a site for further 
functionalization of the polymer through nucleophilic substitution reactions.  Complete 
encapsulation of the iron oxide nanoparticles with PSVBDVB copolymer was achieved 
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through precipitation polymerization process and was evident from the SEM images of 
the copolymer composites.  The results indicated that the iron oxide nanoparticles are not 
only incorporated into the copolymer matrix but also act as nucleation sites for the 
polymerization process to begin.  The polymerization process was found to have no effect 
on the magnetization of the nanoparticles. But the nanoparticles had several effects on the 
resultant polymeric composite size and morphology.  As the loading of the nanoparticles 
was increase during the polymerization process, a decrease in the composite diameter 
was observed.  Also an increase in the polydispersity, and decrease in the uniformity of 
the polymeric composition was detected.   These effects of nanoparticle loading reported 
give insight into parameters that may need to be adjusted in order to obtain mono-
dispersed polymeric composition with better mechanical properties. 
2. In the second phase of the design of drug delivery system, the PSVBDVB polymer was 
replaced by a biocompatible and biodegradable polymer- Poly (lactide-co-glycolide) 
(PLGA).  It has been approved by FDA for human applications.  The PLGA composites 
containing the Fe@FeOx core shell nanoparticles and the drug analog [Ru(bpy) dye] was 
prepared by oil-in water emulsion solvent evaporation technique.  The PLGA composites 
prepared were spherical but had a wider size distribution in the range of 500 nm to 2.5 
μm.  The local heating of the PLGA composites was also achieved by irradiating the 
Fe@FeOx nanoparticles with 2.45 GHz microwave radiations.  The Ru(bpy) dye can be 
quenched by iron oxide nanoparticles. A decrease in the fluorescent intensity of the 
PLGA composites was observed when the composites were heated by microwaves or 
external heat source.  This decrease in intensity observed was speculated to be due to the 
quenching of the released dye by the iron nanoparticles.  The release of the Ru(bpy) dye 
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from the PLGA composites after microwave irradiation was successfully achieved.  Also 
higher Ru(bpy) dye release from the composites by locally heating the sample with 2.45 
GHz microwave pulse compared to externally heating the composite sample was 
demonstrated. 
3. The final step is the design of controlled release drug delivery system with dual modal 
imaging and therapeutic capabilities.  For an efficient drug delivery carrier the carrier size 
plays and important role, so the Fe@FeOx nanoparticles previously used were replaced 
by a chloroform based ferrofluid.  The ferrofluid was synthesized by novel thermolysis 
technique using sodium oleate as the surfactant.  The synthesized ferrofluid consisted of 
mono-dispersed 10±5 nm in diameter.  The nanoparticles were highly magnetic with 
saturation magnetization reaching 105 emu/g and 5 Oe corecivity.  The ferrofluid and the 
drug analog-Rhodamine B dye were encapsulated into the PLGA polymer by modified 
oil-in-water emulsion technique and were confirmed by SEM.  For achieving specific 
targeting capabilities the PLGA composites were functionalized with folic acid. The folic 
acid attachment to the PLGA was confirmed by IR and UV-Vis spectroscopy.  The FA-
PLGA composites were synthesized by the same modified oil-in-water emulsion 
technique. The release of the dye from the PLGA composites when placed in the Rf 
induction coil was determined by fluorescence spectroscopy and a linear increase in the 
fluorescent intensity was observed with time.  The increase in the fluorescent intensity is 
observed indicating that the dye is released from the PLGA composites when locally 
heated.  Also, the controlled release of the dye from the composites was achieved by a 
pulsed Rf treatment.   Increase in the intensity is observed when the composites are 
heated with the Rf pulse ON and rate decreases when the Rf pulse is switched OFF.  This 
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result confirms successful design of a controlled release therapeutic delivery system.  The 
dye is released from the PLGA composites due to the swelling of the polymer and this is 
confirmed by dynamic light scattering measurements.  Magnetic resonance imaging was 
also performed using the PLGA composites which showed enhancement in the T2-
weighted image contrast and thus negligible reduction in the contrast capabilities of the 
iron oxide particles (R2 = 58.7 s
-1
mM
-1
).  The PLGA composites containing the 
Rhodamine B dye and the iron oxide nanoparticles thus constitute a controlled release 
drug delivery system with dual modal imaging and therapeutic capabilities. 
 The present research contributed to the understanding of key parameters in the 
preparation of polymeric composites for therapeutic and imaging purposes.  This work 
has added much to the understanding of the drug delivery system, and part of the ongoing 
work includes on achieving a stable water dispersion of the FA functionalized PLGA 
composites.  Also a detailed cytotoxicity and intracellular uptake study of the composites 
needs to be done for further understanding the biological aspects needs to be concentrated 
for achieving an enhanced drug delivery system capable of replacing the conventional 
routes of drug administration. 
7.1. Future work 
7.1.1. Drug delivery application 
The future step in the designing of the PLGA based drug delivery system is the 
incorporation of the anticancer drugs such as doxorubicin, paclitaxel, or platinum based drugs 
which are known to cause general toxicity.  These drugs can be incorporated in the PLGA 
composites in the same manner by oil-in-water emulsification solvent evaporation technique in 
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which the drug analog- fluorescent dyes were incorporated in the present research.
203
  For 
monitoring the release of the anticancer drugs from the PLGA composites, fluorescent tagged 
anticancer drugs can be used.  The fluorescent tagging of the anticancer drugs makes it easy to 
monitor its release through fluorescent spectroscopy that has been very well established in this 
dissertation work.  Also the drug release can also be determined by HPLC, and UV-Vis 
spectroscopy depending on the type of anticancer drug used.  For example if doxorubicin is used 
as the active therapeutic agent, the encapsulation doxorubicin in PLGA composites can be 
determined by UV-Vis spectroscopy.  Doxorubicin shows a absorbance maxima at 480nm that 
can be utilized to determine the drug concentration using a calibration curve method.
204,205
 
It is also important to study the cytotoxicity of the prepared drug carrier.  Cytotoxicity 
experiments need to be conducted on the prepared PLGA composites.  The initial step would be 
to determine in-vitro cytotoxicity of the PLGA controls- the PLGA composites by itself and the 
PLGA composites containing the magnetic iron/iron oxide nanoparticles and finally the drug 
loaded magnetic PLGA composites.  The next step has to be the in-vitro study of the heating 
effects of the composites on cell lines.  It is necessary to confirm that the heat generated by the 
magnetic nanoparticles is within the defined hyperthermia range (42-46º C).  The increase in the 
temperature of the sample when placed in the Rf induction coil can be measured by utilizing a 
fiber optic based thermometer.  And the final step is to study the specific binding of the PLGA 
composites to the folate receptor on the cancerous cells.   
7.1.2.  Magnetic cell separation 
Magnetic cell separation is a technique of cell sorting by incubating with magnetic 
nanoparticles coated with appropriate targeting ligands such as antibodies or proteins.
156,206
  
These surface coated magnetic nanoparticles bind to the call surface and can be magnetically 
147 
 
separated from the mixture and purified.   The magnetic cell separation technique does not 
require a separating column.
207
  It can be carried out in the sample tubes in liquid phase.  The 
iron oxide nanoparticles loaded poly (styrene-co- vinylbenzylchloride-co-divinylbenzene) 
(PSVBDVB) composites prepared can be further functionalized with an appropriate targeting 
ligand and can be used for magnetic cell separation. The PSVBDVB composites can be 
functionalized with reactive dyes, e. g., Cibachrom Blue F3GA, or Procion Red for purification 
of purification of lysozyme, albumin, and lactate dehydrogenase.
207,208
  The PSVBDVB 
composites can also be functionalized with streptavidin for isolation of biotinylated 
proteins.
209,210
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